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Abstract:  
Background: Smoking and alcohol use have been associated with common genetic variants in 
multiple loci. Rare variants within these loci hold promise in the identification of biological 
mechanisms in substance use. Exome arrays and genotype imputation can now efficiently 
genotype rare nonsynonymous and loss of function variants. Such variants are expected to 
have deleterious functional consequences, and contribute to disease risk. 
Methods: We analyzed ~250,000 rare variants from 16 independent studies genotyped with 
exome arrays and augmented this dataset with imputed data from the UK Biobank. Associations 
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were tested for five phenotypes: cigarettes per day, pack years, smoking initiation, age of 
smoking initiation, and alcoholic drinks per week. We conducted stratified heritability analyses, 
single-variant tests, and gene-based burden tests of nonsynonymous/loss of function coding 
variants. We performed a novel fine mapping analysis to winnow the number of putative causal 
variants within associated loci.  
Results: Meta-analytic sample sizes ranged from 152,348-433,216, depending on the 
phenotype. Rare coding variation explained 1.1-2.2% of phenotypic variance, reflecting 11%-
18% of the total SNP heritability of these phenotypes. We identified 171 genome-wide 
associated loci across all phenotypes. Fine mapping identified putative causal variants with 
double base-pair resolution at 24 of these loci, and between 3 and 10 variants for 65 loci. 20 loci 
contained rare coding variants in the 95% credible intervals.  
Conclusions: Rare coding variation significantly contributes to the heritability of smoking and 
alcohol use. Fine mapping GWAS loci identifies specific variants contributing to the biological 
etiology of substance use behavior.  
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Introduction 
 Tobacco and alcohol use together account for more morbidity and mortality in Western 
society than any other single risk factor or health condition(1). These preventable and 
modifiable behaviors are heritable(2), but previous human and model organism research, 
including genome-wide association studies of common variants, have resulted in few associated 
genetic variants, which most prominently feature genes involved in alcohol/nicotine metabolism 
and nicotinic receptors(3-7).  
Advances in sequencing, genotyping, and genotype imputation now allow cost effective 
investigation of rare and low frequency variants. Compared to common variants (minor allele 
frequency [MAF] > 1%) most commonly used in genome-wide association studies (GWAS), rare 
variants have greater potential to elucidate biological mechanisms of complex traits, including 
substance use and addiction(8, 9). In particular, nonsynonymous and loss of function (LoF) 
coding variants, which result in the loss of normal function of a protein, may have greater 
phenotypic impact and more direct mechanistic interpretation than other variants that do not 
have obvious biological consequences(10, 11). 
No large-scale genome- or exome-wide study of rare variation has been conducted to 
date. The vast majority of existing addiction-related rare variant studies have used targeted 
sequencing of putative addiction-associated loci to discover and test for association in relatively 
small samples. Existing research has led to intriguing leads, including rare variant associations 
in loci that span nicotinic receptor gene clusters(12-21) and alcohol metabolism genes(22-24) 
for nicotine and alcohol dependence, respectively. This strategy has also produced rare variant 
associations in novel loci. In one case, gene-level association tests were used to find an 
association with rare variants in SERINC2(24). In another case, a burden test across PTP4A1, 
PHF3, and EYS showed association with alcohol dependence(25). Unfortunately, these genes 
are not obviously involved in etiological processes related to addiction, and replications have not 
been reported to date. 
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Previous studies have also attempted to leverage information about predicted functional 
consequences of rare mutations to improve association analyses. One study of nicotine 
dependence found significant rare single-variant associations in CHRNB4, but only when 
variants were weighted by their predicted effect on the cellular response to nicotine and 
acetylcholine(26). Such positive findings could benefit from replication, which has not always 
been straightforward. For example, all rare variant associations in addiction are, to our 
knowledge, candidate gene analyses with type I error thresholds based only on the number of 
tests within that region. Historically, such analyses have produced overly optimistic estimates of 
the number of associated loci(27). Genome-wide analyses with more conservative type I error 
thresholds have reported null rare variant findings across an array of phenotypes relevant to 
addiction(28-30). Precisely because genome-wide analyses are conducted on many variants 
across the genome, they are in principle able to discover novel rare variant associations within 
new or known loci. One way to improve power in genome-wide analyses is through genetic 
association meta-analysis, which entails the aggregation of results across many studies to 
achieve large sample sizes. 
Here, we attempted to expand on these previous discoveries by conducting the largest 
meta-analytic investigation of exonic rare variants to date. We conducted an exome-wide 
association meta-analysis of nicotine and alcohol use across 16 studies genotyped on the 
exome array, which genotypes low-frequency nonsynonymous and putative loss of function 
exonic variants. We combined these data with the UK Biobank, which includes approximately 
400,000 individuals of European ancestry with genotype imputation to the Haplotype Reference 
Consortium(31) imputation reference panel and relevant smoking/drinking phenotypes. Sample 
sizes for well-imputed variants were thus enlarged and the availability of noncoding variants 
from UK Biobank enabled comprehensive analysis of genetic architecture(32) and fine 
mapping(33).  
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We conducted single variant and gene-based tests of association with five smoking and 
drinking phenotypes. We applied a novel fine mapping analysis to prioritize causal variants 
using statistical and functional information. We also evaluated the contribution of rare exonic 
variants to the heritability of these phenotypes. Family studies, as well as studies of the 
aggregate effects of common variants, have found both alcohol use and tobacco use to be 
heritable behaviors(30, 34-38). Research on the aggregate contribution of rare variants, 
however, has been scarce, with previous work on related phenotypes in smaller samples failing 
to detect aggregate effects for smoking and alcohol consumption(28). We used meta-analytic 
summary statistics to quantify the contribution to heritability of variants in various functional 
categories and frequency bins. 
Methods and Materials 
Seventeen studies contributed summary statistics for meta-analysis. These studies, their 
sample sizes, and available phenotypes are listed in the online supplement (Tables S1 and 
S2). We augmented our sixteen exome chip cohorts with the UK Biobank, where imputation to 
the Haplotype Reference Consortium panel was used in lieu of an exome chip array. All 
individuals were of European ancestry, as determined by genetic principal components.  
Phenotypes 
 Phenotypes were selected to represent multiple stages of smoking. These included 
initiation, heaviness of use among smokers, and a measure of total lifetime exposure to 
tobacco. For alcohol use only a measure of amount of alcohol use was systematically available 
across studies. The selected phenotypes are relevant to prior GWAS of smoking and alcohol 
use; are commonly available in psychological, medical, and epidemiological data sets; and are 
known to be correlated with measures of substance dependence(4, 39-41). 
1. Cigarettes per day (CigDay). The average number of cigarettes smoked in a day among 
current and former smokers. Studies with binned responses used their existing bins. Studies 
that recorded an integer value binned responses into one of four categories: 1=1-10, 2=11-20, 
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3=21-30, 4=31 or more. Anyone reporting 0 cigarettes per day was coded as missing. This 
phenotype is a component of commonly used measures of nicotine dependence such as the 
Fagerstrom Test for Nicotine Dependence. 
2. Pack Years (PckYr). Defined in the same way as cigarettes per day but not necessarily 
binned, divided by 20 (cigarettes in a pack), and multiplied by number of years smoking. This 
yielded a measure of total overall exposure to tobacco and is relevant to disease outcomes for 
which smoking is a risk factor, such as cancer and chronic obstructive pulmonary disease risk. 
3. Age of Initiation of Smoking (AgeSmk). A measure of early cigarette use. Defined as the age 
at which a participant first started smoking regularly. 
4. Smoking Initiation (SmkInit). A binary variable of whether the individual had ever been a 
regular smoker (1) or not (0), and often defined as having smoked at least 100 cigarettes during 
one’s lifetime. 
5. Drinks per week (DrnkWk). A measure of drinking frequency/quantity. The average number of 
drinks per week in current or former drinkers. 
Genotypes 
 Fourteen of the seventeen studies were genotyped with the Illumina HumanExome 
BeadChip, which contains ~250,000 low-frequency nonsynonymous variants, variants from the 
GWAS catalog, and a small number of variants selected for other purposes. Two studies were 
genotyped on the Illumina Human Core Exome, which includes an additional ~250,000 tag 
SNPs. The remaining study, the UK Biobank, was imputed using Haplotype Reference 
Consortium panel(31, 42), as well as the reference panel by UK 10K and 1000 Genomes 
Project. An integrated callset was released by the UK Biobank team(42). Our UK Biobank 
genetic association analyses were conducted based on the integrated callset with additional 
quality control. 
Generation of Summary Association Statistics 
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Seventeen independent studies (see Table S1) with smoking and drinking phenotypes 
were included in the discovery phase. Individual studies conducted association analysis 
accounting for age, sex, any study-specific covariates, and ancestry principal components (see 
Table S2 for genomic controls), and submitted summary statistics for meta-analysis. For studies 
with related individuals (see Table S1), relatedness was accounted for in linear mixed models 
using empirically estimated kinships from common SNPs(43). Residuals were inverse-
normalized to help ensure well-behaved test statistics for rare variant tests.  
Quality control of per-study summary statistics included evaluation and correction of 
strand flips and allele flips through systematic comparison of alleles and allele frequencies 
against the reference datasets ExAC v2.0, 1000 Genomes Phase 3, and dbSNP. Variants with 
call rates<0.9, or Hardy Weinberg p<1x10-7 were also removed. The latter filter was meant to 
avoid findings that could not be more broadly replicated across the 17 studies.  
Meta-analysis 
Association testing was done in stages. First, we conducted genome-wide association meta-
analysis. Variants with p-values less than the genome-wide significance threshold of 5×10-8 
were deemed statistically significant. Loci were defined as 1 million basepair windows 
surrounding a “sentinel” (most significant) variant in the locus. Overlapping or adjacent loci were 
combined into a single locus. Conditional analysis and fine mapping was then performed within 
each locus. We attempted to replicate one very rare variant (rs36015615 in STARD3 associated 
with CigDay; see results and Table 1) that was available in two other exome chip consortia. 
These were the CHD Exome+ Consortium (N=17,789) and the Consortium for Genetics of 
Smoking Behaviour (N=28,583). Both consortia defined their phenotypes, including cigarettes 
per day similarly, as the usual number of cigarettes smoked in a day corrected for sex, age, 
principal components (and/or genetic relatedness, as appropriate), and inverse-normalized prior 
to association analysis. 
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We also conducted gene-level association tests grouping nonsynonymous, stop gain, 
stop loss and splice variants within each gene, using rareMETALS version 6.0(44). Variant 
annotation was conducted using SEQMINER with RefSeq 1.9(45). Two complementary gene-
level association tests were performed: the sequence kernel association test (SKAT; 46, 47) 
with a MAF cutoff of 1% and a simple burden test(48) that summed the number of rare alleles 
within a given gene, again with a maximum MAF=1%. We chose variants with MAF≤1% as we 
were interested in the contribution of variants with a frequency lower than that which has been 
reliably imputed and tested in past GWAS meta-analyses. We considered a gene association to 
be significant if the p-value surpassed a Bonferroni correction for the number of genes tested for 
a given phenotype and test, assuming approximately 20,000 genes in the genome (.05/20,000 = 
2.5×10-6). 
We performed iterative conditional analysis using a partial correlation based score 
(PCBS) statistic(49), which can perform proper conditional analysis for meta-analysis that 
combines datasets measured using different arrays. PCBS takes GWAS meta-analysis 
summary statistics and LD estimated from the Haplotype Reference Consortium panel as input.  
As a key step to evaluate the contribution of variants within a genome-wide significant 
locus(33), we used our PCBS framework to apply two complementary fine mapping techniques 
to identify putatively causal genetic variants. The first technique was a Bayesian approach 
described previously(50) that estimates the posterior probability of association based upon the 
statistical strength of the association for variants in each locus. We also applied a version of 
fgwas(51) modified to work within PCBS, which assumes that variants in different functional 
categories have potentially different prior probability of association. For loci with a single 
association signal based, effect sizes and variance from single-SNP analyses were used. If a 
locus contained multiple signals, we used effect sizes and variance from conditional analysis 
adjusting for all other index variants in this region.  
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Finally, we attempted to replicate previous rare variant associations referenced in the 
introduction and listed in Table S4. We attempted replication in our phenotypes for any single 
variant when that variant was directly genotyped or imputed. We applied a liberal threshold that 
corrected only for the number of tests conducted for this replication exercise (.05/46=.001). 
Genetic Architecture 
 We performed heritability and genetic correlation analyses using LD score 
regression(52). The method calculates LD scores from the Haplotype Reference Consortium 
and the estimation of heritability with these LD scores then follows established methods(53, 54). 
Heritability was estimated for each trait and partitioned by annotation category and frequency 
bins. First, we annotated variants on the exome chip based upon gene definitions in RefSeq 1.9, 
using SEQMINER version 6.0(55). A variant is classified as coding if it belongs to either one of 
the following categories: nonsynonymous, stop gain, stop loss, and splice. Seven functional 
categories were considered in the model, including intergenic, intron, common coding 
(MAF>0.01), rare coding (MAF<0.01), synonymous, and 3’/5’ untranslated regions. We fitted the 
baseline model with seven categories, and estimated phenotypic variance explained by each 
category. 
Results 
GWAS analyses behaved well, with genomic control values for the GWAS across exome 
chip and UK Biobank imputed variants between 1.05 and 1.3. The intercept for LD Score 
regression ranged between .99 and 1.1, indicating absent or minimal effects of population 
stratification. (Per-study genomic controls can be found in Table S2.) A total of 171 loci were 
identified under the genome-wide significance threshold (p<5×10-8), including 3, 11, 17, 93 and 
47 loci for AgeSmk, CigDay, PckYr, SmkInit, and DrnkWk. A list of all sentinel variants within 
each locus is shown in Table S5. QQ plots and Manhattan plots are available in Figures S1 
and S2. (Additional exploratory GWAS meta-analysis of individuals with significant African 
ancestry are provided in the Supplementary Note [including up to 8,974 individuals from three 
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studies]; see also Table S3, Figure S3 and S4.) The genome-wide significant association 
results included known loci associated with smoking and alcohol use phenotypes. These 
included associations between smoking phenotypes and variants within the CHRNA5-CHRNA3-
CHRNB4 nicotinic receptor cluster, nicotine metabolism gene CYP2A6, and a locus near 
dopamine receptor DRD2. We also replicated previous associations between nonsynonymous 
variant rs1229984 in ADH1B and DrnkWk. Only one very rare variant was associated with any 
of our five phenotypes. This was rs36015615 (MAF=.0002), a nonsynonymous variant in 
STARD3, associated with CigDay (p=3.2×10-8). This novel variant did not replicate in either of 
two replication consortium datasets, the CHD Exome+ Consortium (N=17,789, Beta=-.01, 
p=.94) or the Consortium for Genetics of Smoking Behaviour (N=28,583, Beta=.056, p=.84). 
Based upon the estimated genetic effects in the discovery sample ( = 1.2), the power for 
replication is >99%. However, if we assume the observed effect sizes in the replication datasets 
are correct, there is 5% power for replication based upon this estimated effect. The pattern of 
results may be due to winner’s curse, or the discovered variant may be a false positive finding. 
Additional studies are required to narrow the possible interpretations.  
The fine mapping analysis of all 171 GWAS loci pinpointed putatively causal variants 
with high resolution in some cases. The 95% credible interval for 34% of the loci had <10 SNPs 
and 24 loci had double basepair resolution, including several instances where the sole putative 
causal variant was nonsynonymous and of lower frequency, although in only one case with 
MAF<1%. The resolution increased somewhat when functional information was used to inform 
the prior, with double base-pair resolution at 32 loci, and 44% of loci having <10 SNPs in the 
95% credible interval. Table 1 includes all nonsynonymous or loss of function variants within the 
genome-wide significant loci that had a posterior probability of association greater than .80 from 
at least one of the fine mapping methods. Additional results from the fine mapping analysis are 
available in Tables S6 and S7. Several known functional variants were identified through this 
method, including: rs16969968(56), a nonsynonymous variant in nicotinic receptor gene 
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CHRNA5 associated with CigDay (PPA=.92 and .84 from the fine mapping analysis with, and 
without, functional priors, respectively); rs1229984(57), a nonsynonymous variant in alcohol 
metabolism gene ADH1B associated with DrnkWk (PPA=1.0 and 1.0); and, although with 
somewhat weaker evidence, rs6265(58), a nonsynonymous variant in brain derived 
neurotrophic factor BDNF associated with SmkInit (MAF=.19; PPA=.83 and .32). 
Novel variants in novel genes were also prioritized at high resolution. To take the most 
statistically compelling examples in Table 1, we found rs28929474, a low frequency 
nonsynonymous variant in SERPINA1, associated with DrnkWk (MAF=.02; PPA=1.0 and .95). 
When homozygous, the alternate T (allele frequency = .02; frequency of TT genotype under 
Hardy Weinberg = 4 in 10,000) allele is a leading cause of alpha-1 antitrypsin deficiency. Here, 
we find the same risk allele, the T allele, is associated with an approximately .05 standard 
deviation decrease in drinks per week. We also discovered rs35891966, a variant in NAV2, 
associated with SmkInit (MAF=.07; PPA = 1.0 and .98) at single base-pair resolution. NAV2 is 
involved in neuronal development and previously shown to be differentially expressed between 
smokers and non-smokers, but not previously implicated in GWAS(59).  
Results of gene-based tests are provided in Table 2. A novel gene, rho guanine 
nucleotide exchange factor 37 (ARHGEF37), was associated with Age of Initiation of Smoking 
(p=1.9×10-6). ARHGEF37 has not been widely studied and its function in not well known. 
Another novel gene without an immediate biological interpretation, was HEAT Repeat 
Containing 5A (HEATR5A), associated with Smoking Initiation (p=1.4×10-8). We also discovered 
a significant gene-based association between known alcohol metabolism gene ADH1C and 
Drinks per Week (p=1.4×10-27 and p=1.9×10-40 from the burden and SKAT tests, respectively). 
Finally, even with relaxed p-value thresholds, we failed to replicate genes identified in previous 
rare variant association studies referenced in the introduction (Table S4), with the exception of 
ADH1C and CHRNA5, two loci long known to be associated with alcohol use and smoking, 
respectively. 
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The estimated total SNP heritability for AgeSmk, CigDay, PckYr, SmkInit, and DrnkWk 
was 6%, 9%, 10%, 14% and 16%. Significant phenotypic variance was explained by rare 
nonsynonymous variants for all traits, ranging from 1.0%-2.2% (Table 3). As a fraction of the 
SNP heritability, rare nonsynonymous variants accounted for 11%-18%. Results for all seven 
functional categories are listed in Table S8; appreciable heritability was accounted for by 
common and rare coding variants, and intergenic variants. Variants in the untranslated regions 
and intronic regions contributed less. Almost all pairs of phenotypes were genetically correlated 
(Table 4, Panel A), and the direction of the genetic correlations were in the expected direction. 
For instance, CigDay was positively correlated with DrnkWk (0.2 ± 0.09) , consistent with the 
observation that increased alcohol consumption is correlated with increased tobacco 
consumption. Age of initiation has a negative correlation with all other traits, which is consistent 
with the observation that an earlier age of smoking initiation is correlated with increased tobacco 
and alcohol consumption in adulthood. The patterns and magnitudes of correlation are highly 
similar when considering only rare nonsynonymous variants (Table 4, Panel B). 
Discussion 
 
 With a maximum sample size ranging from 152,348 to 433,216, the present study is the 
largest study to date of low-frequency nonsynonymous and loss of function variants in smoking 
and alcohol use. Our meta-analytic study design combined studies genotyped on the exome 
array with imputed genotypes in the UK Biobank, allowed us to comprehensively evaluate the 
contribution of rare and low frequency variants to the etiology of tobacco and alcohol use. All 
told, we identified 171 genome-wide significant loci for the five phenotypes. 
We showed that the rare variants (MAF≤1%) together explain 1.0% - 2.2% of the 
phenotypic variance for the five traits, amounting to 11-18% of the total SNP heritability. A 
number of putatively causal low frequency nonsynonymous variants in novel genes were 
identified through two complementary fine mapping techniques. These include a variant known 
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to affect alpha-1 antitrypsin deficiency in SERPINA1. The effect of the risk allele resulted in a 
decrease in drinks per week. One interpretation is that this variant leads to impaired liver 
function through alpha-1 antitrypsin deficiency which, in turn, reduces alcohol consumption. 
Interestingly, neither this particular variant or the locus surrounding it was associated with 
smoking phenotypes, even though alpha-1 antitrypsin deficiency also affects lung function over 
time. Other mechanisms by which SERPINA1 exerts its effect on alcohol consumption are 
certainly possible. Another novel nonsynonymous variant was in neuron navigator 2 (NAV2), 
associated with smoking initiation. NAV2 has not previously been associated with substance 
use or addiction. Given its suspected involvement in neuronal growth and migration, a putatively 
causal nonsynonymous variant is a strong candidate for functional follow up experiments. Other 
genes implicated in the fine mapping analysis have less direct interpretations (e.g., HEATR5A) 
and such results will benefit from replication and/or follow-up experiments. In general, fine 
mapping studies narrowed the credible set of likely causal variants to single or double base pair 
resolution for 24 loci (Table S6). Some loci were not amenable to fine mapping, with credible 
intervals containing thousands of SNPs in some cases. Given the cost in money and time of 
conducting functional experiments at the cellular or organismal level, fine mapping likely causal 
variants can be extremely useful in predicting functional consequences and prioritizing variants 
for further work. 
Gene based tests identified a small number of associated genes, including an expected 
association with ADH1C and drinks per week. The other two associated genes, ARHGEF37 and 
HEATR5A, do not lend themselves to ready biological interpretations. 
We showed that rare coding variants available on the exome chip or imputable by the 
Haplotype Reference Consortium, with frequency <1%, explain significant proportions of 
phenotypic variance, and a substantial proportion of the total SNP heritability. The exome chip 
was designed to genotype coding variants uncovered in ~12,000 sequenced exomes. By 
design, it comprehensively ascertained high confidence rare nonsynonymous, splice, and stop 
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variants within those sequences and only sparsely genotypes other classes of variation, 
including common variants. The Haplotype Reference Consortium panel imputed data also have 
limited accuracy when the underlying genetic variants are rare. Therefore, our current 
investigation did not fully explore the genetic architecture of very rare variants (i.e. with 
MAF<0.1%). With the development of larger imputation reference panels, and the availability of 
large scale deep whole genome sequences (such as the Trans-Omics for Precision Medicine 
Study [TOPMed]), we expect to be able to conduct an even more comprehensive analysis of the 
genetic architecture for variants with ever lower frequencies. Ultimately, the discovery of low 
frequency with small effects will require even larger sample sizes. For example, for rare variant 
with MAF of .1% and effects of .2, .15, and 0.1 standard deviations on the phenotype, to identify 
associations at 	 = 5 × 10  with 80% of power, sample sizes of 500,000 890,000 and 
1,990,000 are required. While such numbers seemed astronomical just a few years ago, they 
will indeed be attainable in the next few years with the availability of large biobank datasets and 
ever improving imputation. Another limitation of the present study is the limited samples sizes 
from non-European ancestries, where only exploratory analyses were possible. Substantial 
improvements can be made to the resolution of fine mapping analysis by leveraging disparate 
LD information across samples with diverse ancestry(33). Future research will do well to include 
individuals of diverse ancestry.  
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Table 1. All nonsynonymous/loss of function variants with posterior probability of association > .80 from one of the two fine mapping 
methods. 
SNP REF/ALT N ALT AF GWAS  p-value Beta SE Direction Annotation 
Posterior Probability of 
Association 
Number SNPs (Low 
Frequency Coding SNPs) in 
95% Credible Interval 
         
W/out 
Functional 
Prior 
W/ 
Functional  
Prior (fgwas) 
W/out 
Functional 
Prior 
W/ 
Functional 
Prior (fgwas) 
Cigarettes per Day (CigDay) 
rs36015615a G/A 69,951 .0002 3.2×10-8 1.2 .210 ==+=++=+=X=X+X+++ Nonsynonymous [STARD3] .82 .62 8,997 (6211) 11302 (6232) 
rs16969968 G/A 153,918 .34 2.5×10-139 .096 .0038 +-++-+++++-++++++ Nonsynonymous [CHRNA5] .84 .92 2(0) 2 (0) 
Drinks per Week (DrnkWk) 
rs1260326 T/C 357,854 .61 4.6×10-40 0.032 .0024 +++++++++--++++++ Nonsynonymous [GCKR] 1.0 1.0 1 (0) 1 (0) 
rs1229984 T/C 334,588 .98 2.3×10-173 0.25 .0088 =+-XXXX+XXXX=++++ Nonsynonymous [ADH1B] 1.0 1.0 1 (1) 1 (1) 
rs28929474 C/T 357,854 .02 2.2×10-11 -0.057 .0085 --++-----+++----+ Nonsynonymous [SERPINA1] .95 1.0 1 (1) 1 (1) 
rs1800566 G/A 357,854 .18 2.00×10-8 0.017 .0031 +++++++++++--+++- Nonsynonymous [NQO1] .32 .97 103 (0) 1 (0) 
Smoking Initiation (SmkInit) 
rs2232423 A/G 433,216 .11 1.40×10-8 -0.019 .0034 -+-+---+------ Nonsynonymous [ZSCAN12] .84 .64 502 (0) 2 (0) 
rs35891966 G/A 433,216 .07 1.30×10-8 -0.024 .0042 ---+-+---++--- Nonsynonymous [NAV2] .98 1.0 1 (0) 1 (0) 
rs147052174 G/T 433,216 .02 1.2×10-7 .043 .0080 +++++++++-++++ Nonsynonymous [FAM163A] .81 1.0 2432(66) 1 (0) 
rs6265 C/T 433,216 .19 1.9×10-10 -.017 .0030 ++-++-++--+--- Nonsynonymous [BDNF] .32 .83 25(0) 2 (0) 
rs61754158 C/T 433,216 .01 1.4×10-6 -.055 .0114 --+-+---=+=-+- Nonsynonymous [HEATR5A] .39 .87 9742(195) 9742 (195) 
rs34967813 A/G 433,216 .31 8.1×10-7 -.011 .0023 ----+--+--+--- Nonsynonymous [RYR2] .14 .98 7413(56) 1 (0) 
ars36015615 did not replicate in two additional datasets. See results section. 
Note: REF=reference allele on GRCh37, ALT=alternate allele, N=sample size across all studies that genotyped the variant, ALT AF=allele frequency of the 
alternate allele estimated in the meta-analysis. A variant is considered “rare” if MAF < .01, and low frequency if .01 ≤ MAF < .05. In the DIRECTION 
column each symbol represents the contribution of one of the studies. A “+” indicates the ALT allele had a positive effect in that study; “-“ indicates a 
negative effect. A “=” indicates the variant was monomorphic and “X” indicates it was absent in that study. The order of studies for CigDay and DrnkWk 
was ARIC, UKB, COGA, FINNTWIN, FUSION, GECCO, HRS, ID1000, MEC, METSIM, MHI, MCTFR, NAGOZALC, NESCOG, SardiNIA, TwinsUK, and 
WHI. For SmkInit the order is the same except COGA and MCTFR were not available. See the supplemental materials for study acronym explanations. 
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Table 2. Significant gene based test results, assuming a Bonferroni threshold of .05/20,000=2.5×10-6. 
Phenotype Gene N Number 
Variants 
Beta SE p-value Method 
Age of Initiation of 
Smoking 
ARHGEF37 147,010 17 .08 .017 1.9×10-6 Burden 
Smoking Initiation HEATR5A 427,262 41 -.02 .009 1.4×10-8 SKAT 
Drinks per Week ADH1C 353,265 4 -.15 .014 1.8e-27 Burden 
Drinks per Week ADH1C 353,265 4 -.15 .014 1.9e-40 SKAT 
Note: no significant genes were identified for the other two phenotypes. 
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Table 3: Estimation of Heritability Explained by Variants on Exome Array. We estimate the 
heritability based upon a baseline model with seven different functional categories. The reported 
heritability ℎ is based upon the cumulative value from the functional categories with significant 
heritabilities. We also report the standard deviation (ℎ) and p-values, estimated using 
jackknife. 
 
Annotation Phenotype Heritability Estimates 
  P-Value 
All Variants Age of Initiation of smoking .06 .0049 7.7×10
-35
 
Cigarettes per Day .09 .0019 < 2.2×10
-303
 
Pack Years .10 .0022 < 2.2×10
-303
 
Smoking Initiation .14 .0007 < 2.2×10
-303
 
Drinks per Week .16 .0089 7.3×10
-73
 
Rare Coding 
Variants 
(MAF<.01) 
Age of Initiation of smoking .011 .0015 2.8×10
-2
 
Cigarettes per Day .010 .0006 1.7×10
-2
 
Pack Years .018 .0007 8.5×10
-6
 
Smoking Initiation .022 .0002 3.9×10
-16
 
Drinks per Week .020 .0013 1.8×10
-7
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Table 4: Estimation of Genetic Correlation Between Smoking and Drinking Traits. We 
estimate genetic correlations between five smoking and drinking traits. Genetic correlation 
estimates (̂), their standard deviation (̂) and p-values are reported.  
 
Trait 1 Trait 2 Genetic Correlation 
    P-value 
A. Aggregated Genetic Correlation Induced by All Variants on the Exome Array 
Drinks per Week Smoking Initiation .43 .06 1.7×10
-11
 
Drinks per Week Age of Initiation of Smoking .01 .13 9.3×10
-1
 
Drinks per Week Pack Years .22 .10 2.6×10
-2
 
Drinks per Week Cigarettes per Day .20 .09 3.1×10
-2
 
Smoking Initiation Age of Initiation of Smoking -.64 .11 1.1×10
-8
 
Smoking Initiation Pack Years .45 .08 4.9×10
-8
 
Smoking Initiation Cigarettes per Day .10 .07 1.5×10
-1
 
Age of Initiation of Smoking Pack Years -.63 .17 2.1×10
-4
 
Age of Initiation of Smoking Cigarettes per Day -.26 .16 9.9×10
-2
 
Pack Years Cigarettes per Day .77 .13 2.2×10
-9
 
B. Genetic Correlation Induced by Rare (MAF < 1%) Nonsynonymous Variants 
Drinks per Week Smoking Initiation .49 .08 1.2×10
-10
 
Drinks per Week Age of Initiation of Smoking -.04 .30 8.9×10
-1
 
Drinks per Week Pack Years .08 .02 2.7×10
-4
 
Drinks per Week Cigarettes per Day .09 .02 5.2×10
-5
 
Smoking Initiation Age of Initiation of Smoking -1.10 .21 1.3×10
-7
 
Smoking Initiation Pack Years .63 .08 1.5×10
-14
 
Smoking Initiation Cigarettes per Day .23 .08 3.3×10
-3
 
Age of Initiation of Smoking Pack Years -1.10 .33 1.5×10
-3
 
Age of Initiation of Smoking Cigarettes per Day -.69 .32 3.2×10
-2
 
Pack Years Cigarettes per Day .87 .14 1.4×10
-9
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Exome Chip Meta-Analysis Fine Maps Causal Variants and Elucidates the 
Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use 
 
Supplement 1 
 
 
 
Complete summary statistics 
Complete sets of summary statistics are available for download here: 
https://genome.psych.umn.edu/index.php/GSCAN. 
 
 
Analysis plan 
The analysis plan used by all studies to generate summary statistis is here: 
https://genome.psych.umn.edu/index.php/GSCAN.  
 
 
Exploratory analyses of individuals of African ancestry 
Using the same techniques as for individuals of European ancestry, we conducted a GWAS meta-analysis of 
three cohorts of African and African admixed ancestry. These cohorts were the UK Biobank, The Collaborative 
Study on the Genetics of Alcoholism (COGA), and the Health and Retirement Study (HRS). Sample sizes and 
genomic controls are provided in Table S3. African ancestry in the UK Biobank were identified through inspection 
of genetic principal component 1 against component 2. Individuals with values PC2>0 and PC1>150.  
 
Ultimately, one genome-wide significant hit (rs3806243, p=2.3×10-8) was associated with cigarettes per day at 
the conventional African-ancestry p < 2.5×10-8 threshold. This locus had not been discovered in a prior larger 
meta-analysis of cigarettes per day in African American individuals [1]. Given the lack of replication in the larger 
sample and marginal statistical evidence, no further analyses were conducted. We encourage investigators to 
continue to build cohorts of non-European ancestry. QQ plots and Manhattan plots are provided in Figures S3 
and S4. 
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Sources of funding of individual studies 
COGA: The Collaborative Study on the Genetics of Alcoholism (COGA), Principal Investigators B. Porjesz, V. 
Hesselbrock, H. Edenberg, L. Bierut, includes eleven different centers: University of Connecticut (V. 
Hesselbrock); Indiana University (H.J. Edenberg, J. Nurnberger Jr., T. Foroud); University of Iowa (S. Kuperman, 
J. Kramer); SUNY Downstate (B. Porjesz); Washington University in St. Louis (L. Bierut, J. Rice, K. Bucholz, A. 
Agrawal); University of California at San Diego (M. Schuckit); Rutgers University (J. Tischfield, A. Brooks); 
Department of Biomedical and Health Informatics, The Children’s Hospital of Philadelphia; Department of 
Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA (L. Almasy), Virginia 
Commonwealth University (D. Dick), Icahn School of Medicine at Mount Sinai (A. Goate), and Howard University 
(R. Taylor). Other COGA collaborators include: L. Bauer (University of Connecticut); J. McClintick, L. Wetherill, 
X. Xuei, Y. Liu, D. Lai, S. O’Connor, M. Plawecki, S. Lourens (Indiana University); G. Chan (University of Iowa; 
University of Connecticut); J. Meyers, D. Chorlian, C. Kamarajan, A. Pandey, J. Zhang (SUNY Downstate); J.-
C. Wang, M. Kapoor, S. Bertelsen (Icahn School of Medicine at Mount Sinai); A. Anokhin, V. McCutcheon, S. 
Saccone (Washington University); J. Salvatore, F. Aliev, B. Cho (Virginia Commonwealth University); and Mark 
Kos (University of Texas Rio Grande Valley). A. Parsian and M. Reilly are the NIAAA Staff Collaborators. 
 
We continue to be inspired by our memories of Henri Begleiter and Theodore Reich, founding PI and Co-PI of 
COGA, and also owe a debt of gratitude to other past organizers of COGA, including Ting-Kai Li, P. Michael 
Conneally, Raymond Crowe, and Wendy Reich, for their critical contributions. This national collaborative study 
is supported by NIH Grant U10AA008401 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) 
and the National Institute on Drug Abuse (NIDA). 
 
FTC: Phenotyping and genotyping of the Finnish Twin Cohort (FTC) has been supported by the Academy of 
Finland Center of Excellence in Complex Disease Genetics (grants 213506, 129680), the Academy of Finland 
(grants 100499, 205585, 118555, 141054, 265240, 263278 and 264146 to J. Kaprio), National Institute for Health 
(grant DA12854 to P.A.F. Madden), National Institute of Alcohol Abuse and Alcoholism (grants AA-12502, AA-
00145, and AA-09203 to R. J. Rose and AA15416 and K02AA018755 to D. M. Dick), Sigrid Juselius Foundation 
(to J. Kaprio), Global Research Award for Nicotine Dependence, Pfizer Inc. (to J. Kaprio), and the Welcome 
Trust Sanger Institute, UK. Antti-Pekka Sarin and Samuli Ripatti are acknowledged for genotype data quality 
controls and imputation. Association analyses were run at the ELIXIR Finland node hosted at CSC – IT Center 
for Science for ICT resources. 
 
GECCO: Support for this study came from the National Cancer Institute, National Institutes of Health, U.S. 
Department of Health and Human Services (U01 CA137088; R01CA059045). The authors also thank all those 
at the GECCO Coordinating Center for helping bring together the data and people that made this project possible. 
 
Substudies of GECCO: 
ASTERISK: a Hospital Clinical Research Program (PHRC-BRD09/C) from the University Hospital Center 
of Nantes (CHU de Nantes) and supported by the Regional Council of Pays de la Loire, the Groupement 
des Entreprises Françaises dans la Lutte contre le Cancer (GEFLUC), the Association Anne de Bretagne 
Génétique and the Ligue Régionale Contre le Cancer (LRCC).  We are very grateful to Dr. Bruno Buecher 
without whom this project would not have existed. We also thank all those who agreed to participate in 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Brazel et al.  Supplement 
3 
this study, including the patients and the healthy control persons, as well as all the physicians, technicians 
and students. 
 
CPS-II: The authors thank the CPS-II participants and Study Management Group for their invaluable 
contributions to this research. The authors would also like to acknowledge the contribution to this study 
from central cancer registries supported through the Centers for Disease Control and Prevention National 
Program of Cancer Registries, and cancer registries supported by the National Cancer Institute 
Surveillance Epidemiology and End Results program. 
 
HPFS, NHS: We would like to acknowledge Patrice Soule and Hardeep Ranu of the Dana Farber Harvard 
Cancer Center High-Throughput Polymorphism Core who assisted in the genotyping for NHS, HPFS 
under the supervision of Dr. Immaculata Devivo and Dr. David Hunter, Qin (Carolyn) Guo and Lixue Zhu 
who assisted in programming for NHS and HPFS. We would like to thank the participants and staff of the 
Nurses' Health Study and the Health Professionals Follow-Up Study, for their valuable contributions as 
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Figure S1. QQ plots of GWAS meta-analysis in individuals of European ancestry 
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Figure S2. Manhattan plots of GWAS meta-analysis in individuals of European ancestry 
 
a) Age of Initiation of Regular Smoking (AgeSmk) 
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c) Pack Years (PckYr) 
 
 
d) Smoking Initiation (SmkInit) 
 
 
e) Drinks per Week (DrnkWk) 
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Figure S3. QQ plots of GWAS meta-analysis in individuals of African ancestry 
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Figure S4. Manhattan plots of GWAS meta-analysis in individuals of African ancestry 
 
a) Age of Initiation of Regular Smoking (AgeSmk) 
 
b) Cigarettes per Day (CigDay) 
 
 
c) Pack Years (PckYr) 
 
d) Smoking Initiation (SmkInit) 
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Table S1. Participating cohort descriptions 
Study 
Abbreviation 
Full Study Name Design Array Platform Association Covariates 
ARIC Atherosclerosis Risk in 
Communities 
Community sample of older 
adults 
Illumina 
HumanExome 
 
COGA* Collaborative Study on the 
Genetics of Alcoholism 
Family study of alcoholism Illumina 
HumanCoreExome* 
Sex, age, sex*age, age2, birth cohort, DSM5 alcohol 
dependence 
FTC NAG-FIN, FinnTwin12, 
FinnTwin16, FITSA 
Population-based twin samples 
from the Older and Younger 
Finnish Twin Cohorts 
Illumina 
HumanCoreExome 
Sex, age, age2, current or former smoker (cigarettes per 
day), year of birth, cohort status, BMI. 
FUSION Finland-United States 
Investigation of NIDDM 
Genetics 
Type-2 diabetes case-control Illumina 
HumanExome 
Sex, age, age2, current v. former smoker (cigarettes per 
day), height and weight (drinks per week). 
GECCO Genetics and 
Epidemiology of Colorectal 
Cancer Consortium 
Colorectal cancer case-control Illumina 
HumanExome 
 
HRS Health and Retirement 
Study 
National representative sample 
of older adults 
Illumina 
HumanExome 
Age, age2, sex, age*sex, birth year, PCs 1-4 (European 
ancestry) or PCs 1-10 (African ancestry), current v. 
former smoker (for smoking outcomes), weight, bmi, 
bmi*gender, and current v. former drinker (for drinking 
outcomes) 
ID1000 - National representative sample 
of young adults 
Illumina 
HumanExome 
Age, age2, sex, age*sex, PCs 1-10, current v. former 
smoker (for cigarettes/day, pack years); bmi, weight, 
height, bmi*sex for (drinks per week) 
MEC Multi-Ethnic Cohort  Illumina 
HumanExome 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Brazel et al.  Supplement 
10 
Study 
Abbreviation 
Full Study Name Design Array Platform Association Covariates 
METSIM Metabolic Syndrome in 
Men 
 Illumina 
HumanExome 
Sex, age, age2, current v. former smoker (cigarettes per 
day), height and weight (drinks per week). 
MHI Montreal Heart Institute Community sample of adults 
among visitors, patients and 
employees of the MHI. 
Illumina 
HumanExome 
Sex, age, age2, PCs 1-10, current or former smoker 
status (for cigarettes per day), height and weight (for 
drinks per week). 
MCTFR Minnesota Center for Twin 
and Family Research 
Community-based family cohort Illumina 
HumanExome 
Sex, age, parent-child generation,  
NAGOZALC   Illumina 
HumanExome 
 
NESCOG Netherlands study of 
Cognition, Environment, 
and Genes 
National representative sample 
of adults 
Illumina 
HumanExome 
Age, age2, sex, age*sex, PCs 1-10; current v. former 
smoker (for cigarettes/day, pack years); bmi, weight, 
height, bmi*sex (for drinks/week). 
SardiNIA - Community-based Family Cohort Illumina 
HumanExome 
Sex, age, age2, current v. former smoker (cigarettes per 
day), height and weight (drinks per week).  
TwinsUK - Twin cohort Illumina 
HumanExome 
 
WHI Womens Health Initiative Complex design consisting of 
clinical trials and observational 
cohort. 
Illumina 
HumanExome 
Sex, age, age2, EV1, EV2, EV3 (all phenotypes); current 
v. former smoking (cigarettes per day), height and 
weight (drinks per week). 
UK Biobank** (Stratified by UK BiLEVE 
sample [N~50,000] and 
remainder).  
Community sample of older 
adults, selected for heavy and 
non-smokers 
UK BiLEVE and UK 
Axiom arrays 
Sex, age, age2, current or former smoker (for cigarettes 
per day), PCs 1-15, height, and weight (for drinking 
*The exome array genotyping in COGA was performed in three broader groups comprised of 1059 founder subjects from 118 extended European American families 
and 2815 longitudinally ascertained subjects of mixed ethnicities. The 1059 subjects in 118 families were selected using the ExomePick program 
(http://genome.sph.umich.edu/wiki/ExomePicks) that uses the kinship information to suggests individuals to be sequenced in a large pedigree. Out of 2815 
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longitudinally ascertained subjects 538 subjects were also younger relatives of 1059 EA subjects from 118 extended families.  There were around 726 subjects in 
these EA families that were not genotyped using the exome array. All of EA subjects from 118 families were previously genotyped using Illumina Human OmniExpress 
array 12.VI (Illumina, San Diego, CA, USA).  This gave us an opportunity to infer the dense SNPs in un-genotyped subjects using identity by descent information 
generated through the sparse array using publicly available long range phasing program ChromoPhase (2). We phased genotyped subjects in each pedigree for 
each chromosome by combining the sparse and dense genotypes and used this IBD information to fill in the missing genotypes according to rules of Mendelian 
segregation. The phase of unambiguous SNPs were generated using the population frequency and were imputed according to population based imputation. Using 
this option we were able to guess > 98% missing haplotypes in all of the subjects. After infer process we removed the variants that didn’t follow the rules of Mendelian 
segregation. 
**One member of all pairs of related individuals between first UKB release (150K) and second UKB release (350K) were removed.
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Table S2. Per-study, per-phenotype sample size and genomic control (European ancestry only). 
 Cigarettes per Day Pack Years Age of Initiation 
of Smoking 
Smoking Initiation Drinks per Week 
Study N GC N GC N GC N GC N GC 
ARIC 5381 1.063 5304 1.045 5407 1.096 8970 1.064 5966 1.000 
COGA 1465 .895 1435 1.050 1638 0.923 - - 3398 0.953 
FTC 819 1.048 767 1.012 769 1.059 1467 1.063 1242 0.995 
FUSION 568 1.040 530 1.042 562 1.018 1153 1.016 830 0.997 
GECCO 2916 1.018 2876 1.028 - - 6459 0.993 2077 0.967 
HRS 3303 0.988 3303 0.992 3303 0.998 6393 1.096 4507 0.988 
ID1000 366 0.974 373 1.007 - - 803 0.994 740 0.985 
MEC 1087 0.979 1082 0.963 1086 0.999 1903 0.973 1271 1.064 
METSIM 1374 1.028 1370 1.016 1370 1.026 8146 1.044 6303 1.099 
MHI 4391 1.011 4400 1.016 4420 1.018 6820 1.025 4205 1.022 
MCTFR 2043 0.991 - - - - - - 4757 0.998 
NAGOZALC 671 1.006 646 1.006 647 1.011 1038 1.004 663 0.994 
NESCOG 217 1.004 220 1.000 - - 486 1.038 437 0.980 
SardiNIA 1969 1.009 1967 1.064 1967 1.014 5069 1.082 2516 1.142 
TwinsUK 358 1.039 358 1.010 358 1.006 878 0.971 603 0.989 
WHI 6246 1.031 6236 1.006 - - - - 7213 0.982 
UK Biobank 
(MAF>1%) 
120,744 1.10 120,126 1.08 124,590 1.03 383,631 1.15 311,126 1.06 
UK Biobank 
(MAF≤1%) 
a 1.03 a 1.01 a .96 a .98 a 1.02 
Note: Study abbreviations are defined in Table S1. 
aSample sizes are the same for UK Biobank common and rare variants. 
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Table S3. Per-study, per-phenotype sample size and genomic control (African ancestry only). 
 Cigarettes per Day Pack Years Age of Initiation 
of Smoking 
Smoking Initiation Drinks per Week 
Study N GC N GC N GC N GC N GC 
COGA 476 0.93 457 0.99 494 0.91 - - 1,182 0.94 
HRS 961 1.03 961 1.02 961 1.01 1,746 1.03 980 0.99 
UK Biobank 
(MAF>1%) 
1,248 1.04 1,240 1.01 1,250 1.01 7,228 0.99 5432 1.04 
Note: Study abbreviations are defined in Table S1. 
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Tables S4-S7 are available in Excel spreadsheets for convenience. See Supplement 2. 
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Table S8. Partition of heritablity for variants on exome array. We estimate the “chip” heritability for variants 
on the exome array using LD Score Regression. We consider a model that consists of seven functional 
categories. We report estimates of heritability (ℎ�2), their standard deviation 𝑠𝑠𝑠𝑠�ℎ�2� as well as the p-value and z-
score.  
 
Annotation (𝒉𝒉�𝟐𝟐) 𝒔𝒔𝒔𝒔�𝒉𝒉�𝟐𝟐� p-value z-Score 
Age of Initiation of Smoking 
(Intercept) 1 0.022 0 47 
3' UTR 0.0046 0.0013 0.26 1.1 
5' UTR 0.0089 0.0019 0.14 1.5 
Common Coding Variants 0.014 0.0016 0.0069 2.7 
Intergenic 0.016 0.0036 0.15 1.4 
Intron 0.0042 0.00072 0.066 1.8 
Rare Coding 0.011 0.0015 0.028 2.2 
Synonymous 0.0017 7.00´10-4 0.44 0.77 
Cigarettes per Day 
(Intercept) 1 0.023 0 43 
3' UTR 0.0044 0.00049 1.90´10-1 1.3 
5' UTR 0.0061 0.00072 2.10´10-1 1.2 
Common Coding Variants 0.025 6.00´10-4 1.70´10-9 6 
Intergenic 0.027 0.0014 3.10´10-3 3 
Intron 0.0022 0.00027 2.30´10-1 1.2 
Rare Coding 0.0098 6.00´10-4 1.70´10-2 2.4 
Synonymous 0.015 0.00058 1.20´10-4 3.8 
Drinks per Week 
(Intercept) 1.1 0.027 0 42 
3' UTR 0.015 0.0023 3.00´10-2 2.2 
5' UTR 0.0095 0.0034 3.60´10-1 0.92 
Common Coding Variants 0.035 0.0029 5.10´10-5 4.1 
Intergenic 0.059 0.0065 2.40´10-3 3 
Intron 0.0042 0.0013 2.80´10-1 1.1 
Rare Coding 0.02 0.0013 1.80´10-7 5.2 
Synonymous 0.017 0.0028 4.30´10-2 2 
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Annotation (𝒉𝒉�𝟐𝟐) 𝒔𝒔𝒔𝒔�𝒉𝒉�𝟐𝟐� p-value z-Score 
Pack Years 
(Intercept) 1 0.024 0 43 
3' UTR 0.0041 0.00056 2.10´10-1 1.3 
5' UTR 0.0075 0.00082 1.20´10-1 1.6 
Common Coding Variants 0.018 0.00069 8.80´10-6 4.4 
Intergenic 0.038 0.0016 3.70´10-5 4.1 
Intron 0.002 0.00031 2.70´10-1 1.1 
Rare Coding 0.018 0.00068 8.50´10-6 4.5 
Synonymous 0.012 0.00066 1.30´10-3 3.2 
Smoking Initiation 
(Intercept) 1 3.40´10-2 5.70´10-206 31 
3' UTR 0.019 1.90´10-4 1.40´10-17 8.5 
5' UTR 0.04 2.80´10-4 1.10´10-33 12 
Common Coding Variants 0.019 2.30´10-4 5.40´10-12 6.9 
Intergenic 0.038 5.30´10-4 6.20´10-10 6.2 
Intron 0.0024 1.10´10-4 5.40´10-2 1.9 
Rare Coding 0.022 2.30´10-4 3.90´10-16 8.1 
Synonymous 0.00025 2.40´10-4 9.30´10-1 0.09 
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Phenotype rsID Gene Aggregate P-Value Single P-Value Study Finding from Original Study Pheno VT P-Value Single P-value MAF
Alcohol Dependence rs115360541 SERINC2 - 0.005 Zuo, Wang et al., 2013 Replicated in study Drinks per Week 0.038 - -
Alcohol Dependence - ALDH2 - - Eng et al., 2007 Significant burden test Drinks per Week 0.38 - -
Alcohol Dependence - ADH1B - - Eng et al., 2007 Significant burden test Drinks per Week 0.31 - -
Alcohol Dependence - ADH1C - - Eng et al., 2007 Significant burden test Drinks per Week 6.00E-27 - -
Alcohol Dependence rs149775276 CHRNB3 5.00E-04 2.60E-04 Haller, Kapoor et al., 2014 Top SNP in gene Drinks per Week 0.45 0.97 0.0012
Alcohol Dependence rs111797757 ADH1A - 0.01 Peng et al., 2014 Top SNP in gene Drinks per Week 0.26 0.078 0.087
Alcohol Dependence rs12507078 ADH6 - 0.003 Peng et al., 2014 Top SNP in gene Drinks per Week 0.6 0.32 0.083
Alcohol Dependence rs145341314 ADH5/4 - 0.003 Peng et al., 2014 Top SNP in gene Drinks per Week 0.72 0.7 0.081
Alcohol Dependence rs1497372 ADH1C - 0.004 Peng et al., 2014 Top SNP in gene Drinks per Week 6.00E-27 - -
Alcohol Dependence rs17588403 ADH7 - 0.03 Peng et al., 2014 Top SNP in gene Drinks per Week 0.88 0.12 0.19
Alcohol Dependence rs190914158 ALDH2 - 0.009 Peng et al., 2014 Top SNP in gene Drinks per Week 0.38 - -
Alcohol Dependence rs2226896 ADH4/6 - 0.003 Peng et al., 2014 Top SNP in gene Drinks per Week 0.1 0.33 0.082
Alcohol Dependence rs28914770 ADH1B - 0.018 Peng et al., 2014 Top SNP in gene Drinks per Week 0.31 0.075 0.087
Alcohol Dependence rs7375388 ADH6/1A - 0.003 Peng et al., 2014  Drinks per Week 0.6 1 0.086
Alcohol Dependence rs1229984 ADH1B - 5.88E-05 Way et al., 2015 Top SNP in gene Drinks per Week 0.31 2.27E-173 0.02
Alcohol Dependence rs1789891 ADH1B/ADH1C - 5.31E-05 Way et al., 2015 Top SNP in gene Drinks per Week 0.31 9.14E-19 0.18
Alcohol Dependence rs35961897 SERINC2 1.60E-04 4.10E-05 Zuo, Wang et al., 2013 Top SNP in gene Drinks per Week 0.038 0.41 0.048
Alcohol Dependence rs16834507 SERINC2 - 0.01 Zuo, Wang et al., 2013 Top SNP in gene Drinks per Week 0.038 0.086 6.12E-05
Alcohol Dependence rs77840364 SERINC2 - 0.02 Zuo, Wang et al., 2013 Top SNP in gene Drinks per Week 0.038 - -
Alcohol Dependence rs79051763 PTP4A1 4.20E-03 0.006 Zuo, Wang et al., 2013 Top SNP in gene Drinks per Week - - -
Alcohol Dependence rs114282789 EYS 0.23 0.02 Zuo, Wang et al., 2013 Top SNP in gene Drinks per Week 0.36 - -
Alcohol Dependence rs319919 EYS 0.34 9.50E-04 Zuo, Wang et al., 2013 Top SNP in gene Drinks per Week 0.36 0.21 0.29
Nicotine Dependence - CHRNB4 6.00E-05 - Haller, Druley et al., 2012 Significant burden test Cigarettes per Day 0.24 - -
Nicotine Dependence - CHRNA4 0.04 - Wessel et al., 2010 Significant burden test Cigarettes per Day 0.24 - -
Nicotine Dependence - DBH 1.00E-06 - Yang et al., 2015 Significant burden test Cigarettes per Day 0.84 - -
Nicotine Dependence - NRXN3 1.00E-06 - Yang et al., 2015 Significant burden test Cigarettes per Day 0.4 - -
Nicotine Dependence - NRXN1 2.00E-06 - Yang et al., 2015 Significant burden test Cigarettes per Day 0.42 - -
Nicotine Dependence - TAS2R38 2.00E-06 - Yang et al., 2015 Significant burden test Cigarettes per Day 0.22 - -
Nicotine Dependence - CHRNA9 8.00E-06 - Yang et al., 2015 Significant burden test Cigarettes per Day 0.49 - -
Nicotine Dependence - GRIN3A 8.00E-06 - Yang et al., 2015 Significant burden test Cigarettes per Day 0.96 - -
Nicotine Dependence - CDH13 3.50E-05 - Yang et al., 2015 Significant burden test Cigarettes per Day 0.18 - -
Nicotine Dependence - ARRB2 1.32E-04 - Yang et al., 2015 Significant burden test Cigarettes per Day 0.43 - -
Nicotine Dependence - DNM1 3.53E-04 - Yang et al., 2015 Significant burden test Cigarettes per Day 0.37 - -
Nicotine Dependence - NTRK2 4.25E-04 - Yang et al., 2015 Significant burden test Cigarettes per Day 0.78 - -
Nicotine Dependence - CHRNA4 1.90E-39 - Zuo et al., 2016 Significant burden test Cigarettes per Day 0.12 - -
Nicotine Dependence - CHRNA9 6.10E-30 - Zuo et al., 2016 Significant burden test Cigarettes per Day 0.49 - -
Nicotine Dependence - CHRNA10 3.40E-29 - Zuo et al., 2016 Significant burden test Cigarettes per Day 0.47 - -
Nicotine Dependence - CHRNA7 6.10E-27 - Zuo et al., 2016 Significant burden test Cigarettes per Day 0.91 - -
Nicotine Dependence - CHRNB2 1.30E-18 - Zuo et al., 2016 Significant burden test Cigarettes per Day 0.2 - -
Nicotine Dependence - CHRNE 4.90E-15 - Zuo et al., 2016 Significant burden test Cigarettes per Day 0.57 - -
Nicotine Dependence - CHRNA1 1.20E-14 - Zuo et al., 2016 Significant burden test Cigarettes per Day 0.54 - -
Nicotine Dependence - CHRNA2 5.20E-13 - Zuo et al., 2016 Significant burden test Cigarettes per Day 0.48 - -
Nicotine Dependence rs16969968 CHRNA5 0.01 0.003 Olfson et al., 2016 Top SNP in gene Cigarettes per Day 0.19 2.52E-139 0.34
Original Study GSCAN
Supplementary Table 4. A comparison of our results with previous alcohol and nicotine focused, targeted resequencing based, genetic association studies.
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Nicotine Dependence rs2229961 CHRNA5 - 0.03 Olfson et al., 2016 Top SNP in gene Cigarettes per Day 0.19 2.01E-14 0.019
Nicotine Dependence rs56175056 CHRNA4 - 1.20E-04 Thorgeirsson et al., 2016 Top SNP in gene Cigarettes per Day 0.12 0.11 2.67E-04
Nicotine Dependence rs2072661 CHRNB2 2.00E-03 0.002 Wessel et al., 2010 Top SNP in gene Cigarettes per Day 0.2 0.59 0.24
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Supplementary Table 5. Sentinel GWAS Variants
PHENOTYPE CHROM POS rsID REF ALT AF STAT PVALUE BETA SE N Annotation [Nearest Gene] Distance to Gene
Age of Initiation of Smoking 3 85682087 rs12493563 G T 0.341 43 5.61×10
-11
0.0277 0.00422 124590 Intron[CADM2] 0
Age of Initiation of Smoking 17 31539143 rs8082191 A T 0.279 32.4 1.27×10
-8
0.0254 0.00447 124590 Intron[ACCN1] 0
Age of Initiation of Smoking 20 14844018 rs442467 T C 0.676 42.5 7.18×10
-11
0.0279 0.00428 124590 Intron[MACROD2] 0
Cigarettes per Day 1 154548521 rs2072659 C G 0.102 30 4.28×10
-8
-0.0369 0.00673 120744 Utr3[CHRNB2] 0
Cigarettes per Day 4 2961713 rs2488808 T A 0.308 31.1 2.51×10
-8
-0.0246 0.00441 120744 Intron[NOP14] 0
Cigarettes per Day 7 32273107 rs7806224 T C 0.371 41.9 9.51×10
-11
0.0244 0.00377 150484 Intron[PDE1C] 0
Cigarettes per Day 8 42550498 rs6474412 C T 0.775 66.6 3.40×10
-16
0.0352 0.00432 153918 Intergenic[CHRNB3] 2032
Cigarettes per Day 8 64567670 rs1217106 A G 0.782 34.9 3.51×10
-9
-0.0291 0.00493 120744 Intergenic[YTHDF3] 442388
Cigarettes per Day 9 136478355 rs3025343 G A 0.117 43 5.54×10
-11
0.0368 0.00561 153918 Intergenic[DBH] 23154
Cigarettes per Day 12 4268731 rs113469106 G A 0.057 33.1 8.74×10
-9
0.0505 0.00877 120744 Intergenic[CCND2] 114129
Cigarettes per Day 15 78806023 rs8034191 T C 0.341 633 1.41×10
-139
0.0956 0.0038 153918 Intron[AGPHD1] 0
Cigarettes per Day 17 37814687 rs36015615 G A 0.000163 30.6 3.18×10
-8
1.16 0.20948 69951 Nonsynonymous[STARD3] 0
Cigarettes per Day 19 41353107 rs56113850 T C 0.575 305 2.99×10
-68
0.0719 0.00412 120744 Intron[CYP2A6] 0
Cigarettes per Day 20 61984317 rs6011779 C T 0.806 37.9 7.43×10
-10
-0.0317 0.00514 120744 Intron[CHRNA4] 0
Pack Years 1 110045880 rs4370783 A C 0.115 30.7 3.06×10
-8
-0.0321 0.00579 146945 Intergenic[CYB561D1] 2823
Pack Years 2 45154418 rs7569203 A C 0.317 30.4 3.57×10
-8
0.0218 0.00396 146945 Intergenic[SIX3] 14915
Pack Years 2 105969362 rs62155873 C T 0.127 36.2 1.75×10
-9
0.0334 0.00555 146945 Intergenic[C2orf49] 7568
Pack Years 7 32273107 rs7806224 T C 0.375 67.1 2.57×10
-16
0.0287 0.0035 174410 Intron[PDE1C] 0
Pack Years 8 42550498 rs6474412 C T 0.77 64 1.24×10
-15
0.0319 0.00398 177812 Intergenic[CHRNB3] 2032
Pack Years 9 136478355 rs3025343 G A 0.114 90.1 2.28×10
-21
0.0501 0.00527 177812 Intergenic[DBH] 23214
Pack Years 11 43603300 rs11820132 T C 0.44 36.3 1.70×10
-9
-0.0224 0.00372 146945 Intergenic[MIR670] 22013
Pack Years 13 112179953 rs2026174 C T 0.504 37.8 7.94×10
-10
0.0227 0.00369 146945 Intergenic[C13orf16] 183385
Pack Years 14 104146421 rs4900590 C T 0.324 35.4 2.73×10
-9
0.0234 0.00394 146945 Intron[KLC1] 0
Pack Years 15 78806023 rs8034191 T C 0.338 533 5.81×10
-118
0.0819 0.00355 177812 Intron[AGPHD1] 0
Pack Years 15 89928189 rs150353 T G 0.448 30.8 2.91×10
-8
-0.0205 0.0037 147591 Intron[LOC254559] 0
Pack Years 16 29311500 rs536748263 C T 0.00126 31 2.60×10
-8
0.29 0.0521 146945 Intron[RUNDC2C] 0
Pack Years 16 69972486 rs9302605 T A 0.771 34 5.62×10
-9
0.0256 0.00439 146945 Intron[WWP2] 0
Pack Years 16 89645437 rs369230 G T 0.695 35 3.26×10
-9
0.0237 0.004 146945 Intron[CPNE7] 0
Pack Years 17 27447905 rs12601994 C T 0.156 32.1 1.50×10
-8
0.0288 0.00509 146945 Intron[MYO18A] 0
Pack Years 19 41353107 rs56113850 T C 0.572 107 5.61×10
-25
0.0385 0.00373 146945 Intron[CYP2A6] 0
Pack Years 20 61991833 rs45497800 C T 0.0867 68.2 1.50×10
-16
0.0541 0.00655 146945 Intron[CHRNA4] 0
Smoking Initiation 1 44076019 rs11210887 G A 0.7 48.7 3.00×10
-12
-0.0174 0.00249 384669 Intron[PTPRF] 0
Smoking Initiation 1 66470206 rs2186122 A T 0.561 43.5 4.25×10
-11
0.0152 0.0023 383631 Intron[PDE4B] 0
Smoking Initiation 1 73882478 rs1475064 A G 0.615 30 4.38×10
-8
-0.0121 0.00221 433216 Intergenic[LRRIQ3] 609322
Smoking Initiation 1 74991644 rs1514175 A G 0.575 40.4 2.07×10
-10
-0.0138 0.00217 433216 Intron[FPGT-TNNI3K|TNNI3K] 0
Smoking Initiation 1 91191582 rs72720396 A G 0.231 38.1 6.85×10
-10
-0.0167 0.00271 383631 Intergenic[BARHL2] 8954
Smoking Initiation 1 154154194 rs35761479 G A 0.122 52.5 4.26×10
-13
-0.0253 0.00349 383631 Intron[TPM3] 0
Smoking Initiation 1 210359333 rs55921136 T C 0.203 31 2.56×10
-8
-0.0158 0.00284 383631 Intergenic[SYT14] 22007
Smoking Initiation 2 615140 rs7567570 T C 0.827 46.5 8.96×10
-12
0.0206 0.00302 383631 Intergenic[TMEM18] 52827
Smoking Initiation 2 45154908 rs528301 G A 0.552 51.6 6.93×10
-13
0.0165 0.00229 384669 Intergenic[SIX3] 14387
Smoking Initiation 2 60024857 rs7585579 C G 0.489 47.4 5.65×10
-12
0.0157 0.00228 383631 Intergenic[BCL11A] 653492
Smoking Initiation 2 60526747 rs1029984 G T 0.563 32.1 1.45×10
-8
0.013 0.0023 383631 Intergenic[BCL11A] 151602
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Smoking Initiation 2 64092819 rs140144265 C T 0.00232 29.7 4.92×10
-8
-0.129 0.0237 383631 Intron[UGP2] 0
Smoking Initiation 2 104150791 rs6720941 C T 0.461 65.4 6.06×10
-16
0.0185 0.00229 383631 Intergenic[TMEM182] 716605
Smoking Initiation 2 137542847 rs35702515 G T 0.237 34.3 4.84×10
-9
0.0157 0.00269 383631 Intergenic[THSD7B] 205589
Smoking Initiation 2 145400317 rs1427499 A G 0.711 40 2.57×10
-10
-0.0159 0.00252 383631 Intergenic[DKFZp686O1327] 25192
Smoking Initiation 2 146155371 rs6745444 A G 0.482 85.5 2.36×10
-20
0.0211 0.00228 383631 Intergenic[DKFZp686O1327] 321129
Smoking Initiation 2 155742894 rs2652434 T C 0.533 31.4 2.09×10
-8
0.0128 0.00229 383631 Intergenic[KCNJ3] 30043
Smoking Initiation 2 162891848 rs6432708 C T 0.581 49.1 2.38×10
-12
-0.0162 0.00231 383631 Intron[DPP4] 0
Smoking Initiation 3 5723818 rs4479577 C T 0.482 38.7 4.85×10
-10
0.0142 0.00228 383631 Intergenic[EDEM1] 462139
Smoking Initiation 3 25193102 rs904592 C T 0.482 30.2 3.80×10
-8
0.0126 0.00228 383631 Intergenic[RARB] 276793
Smoking Initiation 3 52874288 rs6445538 T C 0.233 42.4 7.58×10
-11
0.0165 0.00254 433216 Utr3[TMEM110] 0
Smoking Initiation 3 61819535 rs35995169 A G 0.402 33.3 8.00×10
-9
0.0134 0.00233 383631 Intron[PTPRG] 0
Smoking Initiation 3 85460131 rs1549979 C T 0.622 71.3 3.12×10
-17
-0.0187 0.00222 433216 Intron[CADM2] 0
Smoking Initiation 3 86149109 rs73138150 A T 0.324 39 4.20E-10 -0.0152 0.00244 383631 Intergenic[CADM2] 25613
Smoking Initiation 3 117639575 rs62264764 G A 0.149 37.5 9.05×10
-10
-0.0196 0.0032 383631 Intergenic[IGSF11] 979874
Smoking Initiation 3 118302515 rs12053870 T G 0.545 33.3 7.95×10
-9
0.0132 0.00229 383631 Intergenic[IGSF11] 316934
Smoking Initiation 3 157393770 rs963354 C A 0.672 33.5 6.98×10
-9
0.0141 0.00243 384669 Intergenic[C3orf55] 74704
Smoking Initiation 4 28540930 rs13125329 A C 0.258 31.9 1.63×10
-8
0.0147 0.00261 383631 Intergenic[MIR4275] 280254
Smoking Initiation 4 57740334 rs6835108 A G 0.215 36 1.94×10
-9
-0.0167 0.00278 383631 Intergenic[REST] 33707
Smoking Initiation 4 143617304 rs11943397 T C 0.628 35.8 2.22×10
-9
0.0141 0.00236 383631 Intron[INPP4B] 0
Smoking Initiation 4 147948150 rs3827592 G A 0.351 40.1 2.46×10
-10
-0.0151 0.00239 383631 Intergenic[TTC29] 81127
Smoking Initiation 5 22219503 rs4518351 A G 0.444 32.4 1.28×10
-8
0.0131 0.00229 384669 Intron[CDH12] 0
Smoking Initiation 5 60121470 rs62372074 A T 0.148 34.7 3.82×10
-9
0.019 0.00322 383631 Intron[ELOVL7] 0
Smoking Initiation 5 80263403 rs13357015 G A 0.635 30.4 3.54×10
-8
0.0131 0.00237 383631 Intron[RASGRF2] 0
Smoking Initiation 5 87781168 rs10044618 C T 0.432 47.5 5.39×10
-12
-0.0159 0.0023 383631 Intergenic[LOC645323] 55488
Smoking Initiation 5 94202167 rs27003 T C 0.694 33.3 8.02×10
-9
0.0143 0.00248 383631 Intron[MCTP1] 0
Smoking Initiation 5 106825618 rs72789626 T A 0.138 35.7 2.33×10
-9
-0.0198 0.00331 383631 Intron[EFNA5] 0
Smoking Initiation 5 157743295 rs11135030 C T 0.306 37.7 8.17×10
-10
0.0152 0.00248 383631 Intergenic[EBF1] 379662
Smoking Initiation 5 166996722 rs1549212 C T 0.626 37.1 1.14×10
-9
-0.0144 0.00236 383631 Intron[ODZ2] 0
Smoking Initiation 6 28366151 rs2232423 A G 0.111 32.1 1.43×10
-8
-0.0194 0.00342 433216 Nonsynonymous[ZSCAN12] 0
Smoking Initiation 6 29548089 rs926552 G A 0.134 32.8 1.00×10
-8
-0.0181 0.00315 433216 Intergenic[SNORD32B] 1951
Smoking Initiation 6 30857894 rs1264322 G A 0.146 31.7 1.77×10
-8
-0.0171 0.00304 433216 Intron[DDR1] 0
Smoking Initiation 6 31686497 rs15574 G A 0.194 33.5 7.12×10
-9
0.0159 0.00275 422914 Utr3[LY6G6C] 0
Smoking Initiation 6 48121843 rs59263024 T TA 0.1 30.5 3.26×10
-8
0.0388 0.00701 112811 Intergenic[C6orf138] 85379
Smoking Initiation 6 67546542 rs12205538 T C 0.387 36.4 1.60×10
-9
0.0141 0.00234 383631 Intergenic[MCART3P] 1047285
Smoking Initiation 6 93833436 rs6938042 T G 0.339 36 2.01×10
-9
0.0144 0.00241 384669 Intergenic[EPHA7] 116270
Smoking Initiation 6 98888740 rs2132029 C T 0.318 39.5 3.20×10
-10
0.0154 0.00245 383631 Intergenic[POU3F2] 393926
Smoking Initiation 6 101153907 rs6922219 G C 0.47 31.2 2.28×10
-8
0.0128 0.00229 383631 Intron[ASCC3] 0
Smoking Initiation 6 111644332 rs240963 T C 0.841 72.1 2.03×10
-17
-0.0265 0.00312 383631 Intron[REV3L] 0
Smoking Initiation 7 1701592 rs10255004 C T 0.432 42.2 8.28×10
-11
-0.015 0.0023 383631 Intergenic[TFAMP1] 45261
Smoking Initiation 7 3448973 rs2056475 A G 0.746 42.9 5.65×10
-11
-0.0172 0.00262 383631 Intron[SDK1] 0
Smoking Initiation 7 96624257 rs2240294 T A 0.444 30 4.25×10
-8
-0.0126 0.0023 383631 Intron[DLX6-AS1] 0
Smoking Initiation 7 117523709 rs10233018 A G 0.504 43 5.53×10
-11
0.015 0.00228 383631 Intergenic[CTTNBP2] 10264
Smoking Initiation 8 10153082 rs17151637 C T 0.281 35.9 2.12×10
-9
-0.0152 0.00254 383631 Intron[MSRA] 0
Smoking Initiation 8 10836472 rs7010246 G A 0.365 30.7 3.04×10
-8
-0.0131 0.00237 383631 Intron[XKR6] 0
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Smoking Initiation 8 27426077 rs1565735 T A 0.201 67.8 1.77×10
-16
-0.0235 0.00285 383631 Intergenic[EPHX2] 23546
Smoking Initiation 8 59817068 rs1562612 A G 0.504 37.4 9.73×10
-10
-0.0139 0.00228 384669 Intron[TOX] 0
Smoking Initiation 8 92775372 rs10956808 T G 0.422 36.1 1.86×10
-9
-0.0131 0.00218 433216 Intergenic[RUNX1T1] 191934
Smoking Initiation 9 16758107 rs10962568 G C 0.149 38.7 5.00×10
-10
0.0199 0.00321 383631 Intron[BNC2] 0
Smoking Initiation 9 86761781 rs1246264 T C 0.695 38.8 4.82×10
-10
0.0154 0.00248 384669 Intergenic[SLC28A3] 128968
Smoking Initiation 9 128134034 rs7870475 T C 0.475 44.4 2.73×10
-11
0.0152 0.00229 383631 Intergenic[GAPVD1] 6778
Smoking Initiation 9 137975748 rs7019640 C T 0.23 32.7 1.10×10
-8
0.0155 0.00271 383631 Intron[OLFM1] 0
Smoking Initiation 10 21783634 rs12770228 G A 0.315 42.2 8.24×10
-11
0.016 0.00246 383631 Utr3[C10orf114] 0
Smoking Initiation 10 27397454 rs11015535 C T 0.093 31.1 2.46×10
-8
0.0404 0.00725 112811 Intergenic[YME1L1] 1966
Smoking Initiation 10 63674885 rs7921378 G C 0.481 42.8 6.06×10
-11
-0.0149 0.00228 383631 Intron[ARID5B] 0
Smoking Initiation 10 104045951 rs375915173 GT G 0.828 31.7 1.75×10
-8
-0.0314 0.00557 112811 Deletion[GBF1] 0
Smoking Initiation 10 104643241 rs12783782 G A 0.257 59.9 1.00×10
-14
0.0202 0.00261 383631 Intron[AS3MT|C10orf32-AS3MT] 0
Smoking Initiation 10 125680419 rs9423279 C G 0.657 33.3 7.90×10
-9
-0.0139 0.0024 383631 Intergenic[CPXM2] 28954
Smoking Initiation 11 7950797 rs4523689 A G 0.393 32.4 1.25×10
-8
-0.0133 0.00234 383631 Intergenic[OR10A6] 620
Smoking Initiation 11 20129311 rs35891966 G A 0.0719 32.4 1.27×10
-8
-0.0237 0.00416 433216 Nonsynonymous[NAV2] 0
Smoking Initiation 11 27694241 rs2049045 G C 0.187 46.4 9.77×10
-12
-0.0199 0.00293 383631 Intron[BDNF|BDNF-AS1] 0
Smoking Initiation 11 85927213 rs1466802 T C 0.775 38.1 6.68×10
-10
0.0169 0.00274 383631 Intergenic[EED] 28562
Smoking Initiation 11 112839532 rs7948789 A G 0.386 116 6.11×10
-27
0.0252 0.00234 383631 Intron[NCAM1] 0
Smoking Initiation 12 56412487 rs1701704 T G 0.341 30.9 2.70×10
-8
-0.0126 0.00227 433216 Intergenic[IKZF4] 2160
Smoking Initiation 12 57976118 rs11172256 A G 0.257 29.8 4.80×10
-8
0.0143 0.00261 383631 Intron[KIF5A] 0
Smoking Initiation 12 69686203 rs317660 G A 0.718 35.8 2.23×10
-9
-0.0152 0.00254 383631 Intergenic[CPSF6] 18135
Smoking Initiation 12 111904371 rs4766578 T A 0.504 30.8 2.83×10
-8
-0.0127 0.00228 384669 Intron[ATXN2] 0
Smoking Initiation 12 121111214 rs34067374 C T 0.14 30.8 2.80×10
-8
0.0183 0.00329 383631 Intergenic[CABP1] 6058
Smoking Initiation 12 133451277 rs80032242 G A 0.137 30.4 3.54×10
-8
0.0183 0.00332 383631 Intron[CHFR] 0
Smoking Initiation 13 38359684 rs4460944 T C 0.527 31.8 1.68×10
-8
0.0129 0.00229 383631 Intron[TRPC4] 0
Smoking Initiation 13 100548329 rs7322872 C T 0.791 34 5.55×10
-9
-0.0164 0.00281 383631 Utr3[CLYBL] 0
Smoking Initiation 13 101179012 rs837333 T C 0.477 35.7 2.24×10
-9
0.0137 0.00229 383631 Intron[PCCA] 0
Smoking Initiation 14 29500106 rs7141236 T C 0.187 34.6 4.01×10
-9
-0.0172 0.00292 384669 Intergenic[C14orf23] 236110
Smoking Initiation 14 90030280 rs171460 G A 0.26 31 2.52×10
-8
-0.0145 0.0026 383631 Intron[FOXN3] 0
Smoking Initiation 15 47935843 rs1435741 G A 0.43 55 1.18×10
-13
0.0171 0.00231 383631 Intron[SEMA6D] 0
Smoking Initiation 15 54119670 rs766614 T G 0.212 31.8 1.75×10
-8
0.0157 0.00279 384669 Intergenic[WDR72] 67762
Smoking Initiation 16 735921 rs763053 T C 0.225 34.3 4.70×10
-9
-0.016 0.00273 384669 Synonymous[WDR24] 0
Smoking Initiation 16 18058548 rs77878475 T A 0.0858 39.5 3.31×10
-10
-0.0256 0.00408 383631 Intergenic[NOMO2] 455502
Smoking Initiation 16 69567781 rs11646575 G A 0.439 39.6 3.13×10
-10
0.0145 0.0023 383631 Intergenic[NFAT5] 31306
Smoking Initiation 18 77458644 rs522180 C T 0.353 45.6 1.47×10
-11
0.0161 0.00239 383631 Intron[CTDP1] 0
Smoking Initiation 19 4474725 rs76608582 C A 0.0482 32.6 1.15×10
-8
-0.0304 0.00533 383631 Intron[HDGFRP2] 0
Smoking Initiation 20 29893501 rs6061162 C T 0.912 29.8 4.83×10
-8
0.022 0.00402 383631 Intron[DEFB116] 0
Smoking Initiation 20 31140165 rs4911241 C T 0.239 51.9 5.88×10
-13
0.0182 0.00252 433216 Intergenic[LOC149950] 35093
Drinks per Week 1 4569436 rs780569 T A 0.708 33.2 8.47×10
-9
-0.0161 0.00279 311126 Intergenic[LOC284661] 84866
Drinks per Week 1 95730588 rs3886141 G C 0.409 31.5 1.96×10
-8
-0.0145 0.00258 311126 Intergenic[RWDD3] 17791
Drinks per Week 1 165119792 rs10753661 G A 0.684 33.2 8.36×10
-9
-0.0157 0.00273 311126 Intergenic[LMX1A] 51267
Drinks per Week 2 27730940 rs1260326 T C 0.608 176 4.58×10
-40
0.0321 0.00242 357854 Nonsynonymous[GCKR] 0
Drinks per Week 2 44271496 rs75120545 C T 0.0302 33.7 6.29×10
-9
-0.043 0.00741 311126 Intergenic[LRPPRC] 48316
Drinks per Week 2 45154908 rs528301 G A 0.553 69.6 7.12×10
-17
0.0213 0.00255 311789 Intergenic[SIX3] 14387
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Drinks per Week 2 144272376 rs4233567 C T 0.364 37.5 8.92×10
-10
-0.0161 0.00263 311126 Intron[ARHGAP15] 0
Drinks per Week 3 85049088 rs1872552 G A 0.399 44.4 2.73×10
-11
0.0172 0.00259 311789 Intron[CADM2] 0
Drinks per Week 3 85593584 rs6780346 C T 0.621 41.1 1.47×10
-10
-0.0168 0.00261 311126 Intron[CADM2] 0
Drinks per Week 4 39413780 rs28712821 G A 0.608 187 1.67×10
-42
0.0355 0.0026 311126 Intron[KLB] 0
Drinks per Week 4 42117559 rs16854020 G A 0.13 37.3 1.02×10
-9
0.023 0.00377 311126 Utr3[BEND4] 0
Drinks per Week 4 97853880 rs143118954 T A 0.00233 35.8 2.16×10
-9
-0.157 0.02627 311126 Intergenic[C4orf37] 626164
Drinks per Week 4 98373818 rs143475242 C T 0.00341 49.5 2.00×10
-12
-0.153 0.02175 311126 Intergenic[C4orf37] 106226
Drinks per Week 4 98979582 rs1727284 C G 0.00147 50.4 1.26×10
-12
-0.235 0.03305 311126 Intron[C4orf37] 0
Drinks per Week 4 99713350 rs144198753 C T 0.00935 304 4.41×10
-68
-0.23 0.01317 311126 Intergenic[EIF4E] 86341
Drinks per Week 4 100239319 rs1229984 T C 0.98 788 2.27×10
-173
0.246 0.00878 334588 Nonsynonymous[ADH1B] 0
Drinks per Week 4 100919254 rs150021439 C T 0.0044 96.1 1.12×10
-22
-0.188 0.01914 311126 Intergenic[LOC256880] 45686
Drinks per Week 4 103188709 rs13107325 C T 0.0721 70.3 4.97×10
-17
-0.0383 0.00457 357854 Nonsynonymous[SLC39A8] 0
Drinks per Week 4 143617304 rs11943397 T C 0.629 32.1 1.43×10
-8
0.0149 0.00262 311126 Intron[INPP4B] 0
Drinks per Week 6 12903957 rs9349379 A G 0.406 30.8 2.85×10
-8
0.0134 0.00241 357854 Intron[PHACTR1] 0
Drinks per Week 7 69793380 rs6978841 T A 0.184 31.3 2.24×10
-8
-0.0183 0.00327 311126 Intron[AUTS2] 0
Drinks per Week 7 153489725 rs6969458 G A 0.466 44.6 2.45×10
-11
0.017 0.00254 311126 Intergenic[DPP6] 94696
Drinks per Week 9 108755622 rs55932213 A G 0.746 32.2 1.41×10
-8
0.0165 0.00291 311126 Intergenic[TMEM38B] 218228
Drinks per Week 9 109330236 rs4743009 G A 0.201 33.5 6.98×10
-9
-0.0183 0.00317 311126 Intergenic[ZNF462] 295381
Drinks per Week 10 102626510 rs61873510 G T 0.326 33.5 7.14×10
-9
-0.0157 0.0027 311126 Intergenic[PAX2] 36831
Drinks per Week 11 33204159 rs4756121 G C 0.688 42.8 6.08×10
-11
0.0179 0.00274 311126 Intron[LOC338739] 0
Drinks per Week 11 47457539 rs11604680 A G 0.32 40.8 1.69×10
-10
-0.0174 0.00272 311126 Intergenic[RAPSN] 1776
Drinks per Week 11 113412443 rs4309187 A C 0.684 45.9 1.25×10
-11
0.0185 0.00273 311126 Intergenic[DRD2] 66456
Drinks per Week 11 116073667 rs1894071 A G 0.857 30.2 3.94×10
-8
0.0199 0.00362 311126 Intergenic[LOC283143] 442792
Drinks per Week 11 121501406 rs10790449 T C 0.465 33.6 6.91×10
-9
0.0147 0.00254 311126 Utr3[SORL1] 0
Drinks per Week 14 57281154 rs962961 C T 0.326 34.7 3.88×10
-9
-0.0159 0.00271 311126 Intron[OTX2OS1] 0
Drinks per Week 14 58833909 rs57044214 G A 0.284 35.1 3.17×10
-9
0.0166 0.00281 311126 Intron[ARID4A] 0
Drinks per Week 14 94844947 rs28929474 C T 0.0198 44.8 2.22×10
-11
-0.0568 0.00849 357854 Nonsynonymous[SERPINA1] 0
Drinks per Week 16 24810681 rs17177078 C T 0.0554 34.9 3.45×10
-9
-0.0327 0.00554 311126 Intron[TNRC6A] 0
Drinks per Week 16 28539848 rs4788084 C T 0.418 31.1 2.46×10
-8
-0.0134 0.0024 355949 Intergenic[NUPR1] 8923
Drinks per Week 16 69745145 rs1800566 G A 0.183 31.5 1.99×10
-8
0.0172 0.00306 357854 Nonsynonymous[NQO1] 0
Drinks per Week 16 72356964 rs11648570 T C 0.107 31.5 2.04×10
-8
0.023 0.00409 311126 Intergenic[PMFBP1] 150733
Drinks per Week 16 73912588 rs1104608 G C 0.426 40.6 1.87×10
-10
-0.0163 0.00256 311126 Intergenic[PSMD7] 418045
Drinks per Week 17 43754850 rs62055691 T C 0.225 99.7 1.78×10
-23
-0.0303 0.00303 311126 Intron[CRHR1] 0
Drinks per Week 17 44285531 rs2469933 G A 0.225 94.7 2.27×10
-22
-0.0295 0.00303 311789 Intron[KIAA1267] 0
Drinks per Week 17 44843136 rs199528 C T 0.223 88.4 5.27×10
-21
-0.0286 0.00304 311126 Intron[WNT3] 0
Drinks per Week 18 40735531 rs62092069 G A 0.373 31.9 1.60×10
-8
0.0148 0.00262 311126 Intergenic[RIT2] 39911
Drinks per Week 19 49248730 rs838145 G A 0.541 46.6 8.86×10
-12
-0.0174 0.00254 311126 Intron[IZUMO1] 0
Drinks per Week 20 18693080 rs62217022 A G 0.396 32.6 1.10×10
-8
-0.0148 0.00259 311126 Intron[DTD1] 0
Drinks per Week 20 31607551 rs61734341 G C 0.0598 32.7 1.09×10
-8
-0.0285 0.00499 357854 Nonsynonymous[BPIL1] 0
Drinks per Week 22 41941243 rs9607812 G A 0.187 38 7.21×10
-10
-0.02 0.00325 311126 Intergenic[POLR3H] 719
Drinks per Week 22 46481623 rs17884691 G A 0.248 32.7 1.08×10
-8
-0.0168 0.00294 311126 Intergenic[LOC400931] 208
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Supplementary Table 6. Bayesian Fine Mapping of all GWAS-significant variants, with Prior Informed by Statistical Association Only
PHENOTYPE CHROM POS rsID REF ALT AF STAT PVALUE BETA SE N SNPs in Interval Interval SizeInterval Start Interval End Annotation [Nearest Gene]
Age of Initiation of Smoking 3 85682087 rs12493563G T 0.341 43 5.61×10
-11
0.0277 0.00422 124590 59 177051 85521990 85699040 Intron[CADM2]
Age of Initiation of Smoking 17 31539143 rs8082191 A T 0.279 32.4 1.27×10
-8
0.0254 0.00447 124590 50 32052 31539143 31571194 Intron[ACCN1]
Age of Initiation of Smoking 20 14844018 rs442467 T C 0.676 42.5 7.18×10
-11
0.0279 0.00428 124590 29 67700 14817453 14885152 Intron[MACROD2]
Cigarettes per Day 1 154548521 rs2072659 C G 0.102 30 4.28×10
-8
-0.0369 0.00673 120744 2 472 154548521 154548992 Utr3[CHRNB2]
Cigarettes per Day 4 2961713 rs2488808 T A 0.308 31.1 2.51×10
-8
-0.0246 0.00441 120744 121 154665 2873835 3028499 Intron[NOP14]
Cigarettes per Day 7 32273107 rs7806224 T C 0.371 41.9 9.51×10
-11
0.0244 0.00377 150484 48 117761 32261458 32379218 Intron[PDE1C]
Cigarettes per Day 8 42550498 rs6474412 C T 0.775 66.6 3.40×10
-16
0.0352 0.00432 153918 1 1 42550498 42550498 Intergenic[CHRNB3]
Cigarettes per Day 8 64567670 rs1217106 A G 0.782 34.9 3.51×10
-9
-0.0291 0.00493 120744 127 335003 64540485 64875487 Intergenic[YTHDF3]
Cigarettes per Day 9 136478355 rs3025343 G A 0.117 43 5.54×10
-11
0.0368 0.00561 153918 8 25071 136460224 136485294 Intergenic[DBH]
Cigarettes per Day 12 4268731 rs113469106G A 0.057 33.1 8.74×10
-9
0.0505 0.00877 120744 11 126043 4156808 4282850 Intergenic[CCND2]
Cigarettes per Day 15 78806023 rs8034191 T C 0.341 6331.41×10
-139
0.0956 0.0038 153918 2 65266 78806023 78871288 Intron[AGPHD1]
Cigarettes per Day 15 78896547 rs938682 G A 0.777 382 4.44×10
-85
0.0846 0.00433 153918 2 11486 78896547 78908032 Intron[CHRNA3]
Cigarettes per Day 15 78918726 rs4344703 G T 0.68 248 7.32×10
-56
-0.0845 0.00536 79862 15 86006 78862845 78948850 Intron[CHRNB4]
Cigarettes per Day 17 37814687 rs36015615G A 0.000163 30.6 3.18×10
-8
1.16 0.20948 69951 8997 999750 37314891 38314640 Nonsynonymous[STARD3]
Cigarettes per Day 19 41353107 rs56113850T C 0.575 305 2.99×10
-68
0.0719 0.00412 120744 3 13822 41353107 41366928 Intron[CYP2A6]
Cigarettes per Day 19 41356379 rs28399433A C 0.0626 90.3 2.00×10
-21
-0.0799 0.0084 120744 9 39192 41333284 41372475 Upstream[CYP2A6]
Cigarettes per Day 19 41371480 rs117824460A G 0.0288 157 4.82×10
-36
-0.153 0.01217 120744 2 16948 41354533 41371480 Intergenic[CYP2A7]
Cigarettes per Day 19 41406448 rs117540499G A 0.0229 110 1.08×10
-25
-0.143 0.01361 120744 14 72606 41335269 41407874 Intergenic[CYP2A7]
Cigarettes per Day 20 61984317 rs6011779 C T 0.806 37.9 7.43×10
-10
-0.0317 0.00514 120744 3 7689 61984317 61992005 Intron[CHRNA4]
Pack Years 1 110045880 rs4370783 A C 0.115 30.7 3.06×10
-8
-0.0321 0.00579 146945 3 10415 110036919 110047333 Intergenic[CYB561D1]
Pack Years 2 45154418 rs7569203 A C 0.317 30.4 3.57×10
-8
0.0218 0.00396 146945 18 57384 105915711 105973094 Intergenic[SIX3]
Pack Years 2 105969362 rs62155873C T 0.127 36.2 1.75×10
-9
0.0334 0.00555 146945 9 17632 45152522 45170153 Intergenic[C2orf49]
Pack Years 7 32273107 rs7806224 T C 0.375 67.1 2.57×10
-16
0.0287 0.0035 174410 40 72185 32261458 32333642 Intron[PDE1C]
Pack Years 8 42550498 rs6474412 C T 0.77 64 1.24×10
-15
0.0319 0.00398 177812 29 19541 42544017 42563557 Intergenic[CHRNB3]
Pack Years 9 136478355 rs3025343 G A 0.114 90.1 2.28×10
-21
0.0501 0.00527 177812 1 1 136478355 136478355 Intergenic[DBH]
Pack Years 11 43603300 rs11820132T C 0.44 36.3 1.70×10
-9
-0.0224 0.00372 146945 33 126471 43601860 43728330 Intergenic[MIR670]
Pack Years 13 112179953 rs2026174 C T 0.504 37.8 7.94×10
-10
0.0227 0.00369 146945 5 6331 112179953 112186283 Intergenic[C13orf16]
Pack Years 14 104146421 rs4900590 C T 0.324 35.4 2.73×10
-9
0.0234 0.00394 146945 38 116843 104067895 104184737 Intron[KLC1]
Pack Years 15 78806023 rs8034191 T C 0.338 5335.81×10
-118
0.0819 0.00355 177812 8 86930 78806023 78892952 Intron[AGPHD1]
Pack Years 15 78896547 rs938682 G A 0.773 304 5.39×10
-68
0.0698 0.00401 177812 2 11486 78896547 78908032 Intron[CHRNA3]
Pack Years 15 78918726 rs4344703 G T 0.68 284 8.47×10
-64
-0.0667 0.00395 146945 34 329428 78642718 78972145 Intron[CHRNB4]
Pack Years 15 78962803 . C T 0.0511 100 1.44×10
-23
-0.0838 0.00838 146945 1 1 78962803 78962803 Intergenic[CHRNB4]
Pack Years 15 79004642 . C T 0.754 48.7 2.94×10
-12
0.0299 0.00428 146945 1 1 79004642 79004642 Intergenic[LOC646938]
Pack Years 15 79052227 . T C 0.222 29.7 5.07×10
-8
-0.0242 0.00444 146945 5 388223 78664005 79052227 Intron[ADAMTS7]
Pack Years 15 79078638 rs142833365T C 0.00431 20.9 4.77×10
-6
0.129 0.02816 146945 23 505793 78642718 79148510 Intron[ADAMTS7]
Pack Years 15 89928189 rs150353 T G 0.448 30.8 2.91×10
-8
-0.0205 0.0037 147591 11 18402 89927560 89945961 Intron[LOC254559]
Pack Years 16 29311500 rs536748263C T 0.00126 31 2.60×10
-8
0.29 0.0521 146945 82 72034 28823097 28895130 Intron[RUNDC2C]
Pack Years 16 69972486 rs9302605 T A 0.771 34 5.62×10
-9
0.0256 0.00439 146945 81 441506 69556583 69998088 Intron[WWP2]
Pack Years 16 89645437 rs369230 G T 0.695 35 3.26×10
-9
0.0237 0.004 146945 1 1 89645437 89645437 Intron[CPNE7]
Pack Years 17 27447905 rs12601994C T 0.156 32.1 1.50×10
-8
0.0288 0.00509 146945 7 65845 27382061 27447905 Intron[MYO18A]
Pack Years 19 41353107 rs56113850T C 0.572 107 5.61×10
-25
0.0385 0.00373 146945 3 11879 41341229 41353107 Intron[CYP2A6]
Pack Years 19 41371480 rs117824460A G 0.0274 51.7 6.51×10
-13
-0.0813 0.01131 146945 2 16948 41354533 41371480 Intergenic[CYP2A7]
Pack Years 20 61991833 rs45497800C T 0.0867 68.2 1.50×10
-16
0.0541 0.00655 146945 3 7900 61983934 61991833 Intron[CHRNA4]
Smoking Initiation 1 43999327 rs71636604G T 0.255 8.67 3.24×10
-3
0.00772 0.00262 383631 12 44180 43955148 43999327 Intron[PTPRF]
Smoking Initiation 1 44076019 rs11210887G A 0.7 48.7 3.00×10
-12
-0.0174 0.00249 384669 9 62400 44037685 44100084 Intron[PTPRF]
Smoking Initiation 1 66470206 rs2186122 A T 0.561 43.5 4.25×10
-11
0.0152 0.0023 383631 18 88784 66392405 66481188 Intron[PDE4B]
Smoking Initiation 1 73882478 rs1475064 A G 0.615 30 4.38×10
-8
-0.0121 0.00221 433216 464 648514 73435171 74083684 Intergenic[LRRIQ3]
Smoking Initiation 1 74991644 rs1514175 A G 0.575 40.4 2.07×10
-10
-0.0138 0.00217 433216 25 28851 74977870 75006720 Intron[FPGT-TNNI3K|TNNI3K]
Smoking Initiation 1 91191582 rs72720396A G 0.231 38.1 6.85×10
-10
-0.0167 0.00271 383631 9 6446 91189731 91196176 Intergenic[BARHL2]
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Smoking Initiation 1 210359333 rs55921136T C 0.203 31 2.56×10
-8
-0.0158 0.00284 383631 16 247370 210176170 210423539 Intergenic[SYT14]
Smoking Initiation 2 615140 rs7567570 T C 0.827 46.5 8.96×10
-12
0.0206 0.00302 383631 164 38442 615140 653581 Intergenic[TMEM18]
Smoking Initiation 2 45154908 rs528301 G A 0.552 51.6 6.93×10
-13
0.0165 0.00229 384669 17 32700 45134871 45167570 Intergenic[SIX3]
Smoking Initiation 2 60024857 rs7585579 C G 0.489 47.4 5.65×10
-12
0.0157 0.00228 383631 9 157818 60000304 60158121 Intergenic[BCL11A]
Smoking Initiation 2 60475008 rs359240 G A 0.607 35.6 2.41×10
-9
0.0139 0.00234 383631 70 60815 60470926 60531740 Intergenic[BCL11A]
Smoking Initiation 2 64092819 rs140144265C T 0.00232 29.7 4.92×10
-8
-0.129 0.0237 383631 7200 999920 63592820 64592739 Intron[UGP2]
Smoking Initiation 2 104150791 rs6720941 C T 0.461 65.4 6.06×10
-16
0.0185 0.00229 383631 182 241178 104057364 104298541 Intergenic[TMEM182]
Smoking Initiation 2 137542847 rs35702515G T 0.237 34.3 4.84×10
-9
0.0157 0.00269 383631 143 265371 137359506 137624876 Intergenic[THSD7B]
Smoking Initiation 2 145400317 rs1427499 A G 0.711 40 2.57×10
-10
-0.0159 0.00252 383631 2 11955 145400317 145412271 Intergenic[DKFZp686O1327]
Smoking Initiation 2 146155371 rs6745444 A G 0.482 85.5 2.36×10
-20
0.0211 0.00228 383631 13 13590 146143090 146156679 Intergenic[DKFZp686O1327]
Smoking Initiation 2 155742894 rs2652434 T C 0.533 31.4 2.09×10
-8
0.0128 0.00229 383631 29 433295 155670875 156104169 Intergenic[KCNJ3]
Smoking Initiation 2 162891848 rs6432708 C T 0.581 49.1 2.38×10
-12
-0.0162 0.00231 383631 30 93268 162798581 162891848 Intron[DPP4]
Smoking Initiation 3 5723818 rs4479577 C T 0.482 38.7 4.85×10
-10
0.0142 0.00228 383631 12 6331 5720948 5727278 Intergenic[EDEM1]
Smoking Initiation 3 25193102 rs904592 C T 0.482 30.2 3.80×10
-8
0.0126 0.00228 383631 109 147649 25147940 25295588 Intergenic[RARB]
Smoking Initiation 3 52874288 rs6445538 T C 0.233 42.4 7.58×10
-11
0.0165 0.00254 433216 9 39219 52852538 52891756 Utr3[TMEM110]
Smoking Initiation 3 61819535 rs35995169A G 0.402 33.3 8.00×10
-9
0.0134 0.00233 383631 57 69201 61809160 61878360 Intron[PTPRG]
Smoking Initiation 3 85460131 rs1549979 C T 0.622 71.3 3.12×10
-17
-0.0187 0.00222 433216 307 242238 85407980 85650217 Intron[CADM2]
Smoking Initiation 3 85985324 rs66680800G T 0.399 35.8 2.21×10
-9
-0.0139 0.00233 383631 85 218344 85868529 86086872 Intron[CADM2]
Smoking Initiation 3 117639575 rs62264764G A 0.149 37.5 9.05×10
-10
-0.0196 0.0032 383631 155 449454 117517339 117966792 Intergenic[IGSF11]
Smoking Initiation 3 118302515 rs12053870T G 0.545 33.3 7.95×10
-9
0.0132 0.00229 383631 59 107857 118294235 118402091 Intergenic[IGSF11]
Smoking Initiation 3 157393770 rs963354 C A 0.672 33.5 6.98×10
-9
0.0141 0.00243 384669 37 200909 157377765 157578673 Intergenic[C3orf55]
Smoking Initiation 4 28540930 rs13125329A C 0.258 31.9 1.63×10
-8
0.0147 0.00261 383631 183 544291 28191284 28735574 Intergenic[MIR4275]
Smoking Initiation 4 57740334 rs6835108 A G 0.215 36 1.94×10
-9
-0.0167 0.00278 383631 16 5239 57738345 57743583 Intergenic[REST]
Smoking Initiation 4 143617304 rs11943397T C 0.628 35.8 2.22×10
-9
0.0141 0.00236 383631 19 122574 143500223 143622796 Intron[INPP4B]
Smoking Initiation 4 147948150 rs3827592 G A 0.351 40.1 2.46×10
-10
-0.0151 0.00239 383631 89 219281 147748826 147968106 Intergenic[TTC29]
Smoking Initiation 5 22219503 rs4518351 A G 0.444 32.4 1.28×10
-8
0.0131 0.00229 384669 21 71936 22160029 22231964 Intron[CDH12]
Smoking Initiation 5 60121470 rs62372074A T 0.148 34.7 3.82×10
-9
0.019 0.00322 383631 71 421607 60057718 60479324 Intron[ELOVL7]
Smoking Initiation 5 80263403 rs13357015G A 0.635 30.4 3.54×10
-8
0.0131 0.00237 383631 6 23327 80240539 80263865 Intron[RASGRF2]
Smoking Initiation 5 87781168 rs10044618C T 0.432 47.5 5.39×10
-12
-0.0159 0.0023 383631 21 100175 87680994 87781168 Intergenic[LOC645323]
Smoking Initiation 5 94202167 rs27003 T C 0.694 33.3 8.02×10
-9
0.0143 0.00248 383631 4 27588 94198290 94225877 Intron[MCTP1]
Smoking Initiation 5 106825618 rs72789626T A 0.138 35.7 2.33×10
-9
-0.0198 0.00331 383631 7 15162 106825618 106840779 Intron[EFNA5]
Smoking Initiation 5 157743295 rs11135030C T 0.306 37.7 8.17×10
-10
0.0152 0.00248 383631 29 20603 157722715 157743317 Intergenic[EBF1]
Smoking Initiation 5 166996722 rs1549212 C T 0.626 37.1 1.14×10
-9
-0.0144 0.00236 383631 22 9801 166988585 166998385 Intron[ODZ2]
Smoking Initiation 6 28366151 rs2232423 A G 0.111 32.1 1.43×10
-8
-0.0194 0.00342 433216 502 998466 27866384 28864849 Nonsynonymous[ZSCAN12]
Smoking Initiation 6 29548089 rs926552 G A 0.134 32.8 1.00×10
-8
-0.0181 0.00315 433216 465 981009 29057639 30038647 Intergenic[SNORD32B]
Smoking Initiation 6 30857894 rs1264322 G A 0.146 31.7 1.77×10
-8
-0.0171 0.00304 433216 55 763863 30365448 31129310 Intron[DDR1]
Smoking Initiation 6 31686497 rs15574 G A 0.194 33.5 7.12×10
-9
0.0159 0.00275 422914 18 540260 31605448 32145707 Utr3[LY6G6C]
Smoking Initiation 6 48121843 NA T TA 0.1 30.5 3.26×10
-8
0.0388 0.00701 112811 4 110489 48121843 48232331 Intergenic[C6orf138]
Smoking Initiation 6 67546542 rs12205538T C 0.387 36.4 1.60×10
-9
0.0141 0.00234 383631 105 150542 67405337 67555878 Intergenic[MCART3P]
Smoking Initiation 6 93833436 rs6938042 T G 0.339 36 2.01×10
-9
0.0144 0.00241 384669 3 9011 93833436 93842446 Intergenic[EPHA7]
Smoking Initiation 6 98888740 rs2132029 C T 0.318 39.5 3.20×10
-10
0.0154 0.00245 383631 103 261293 98631890 98893182 Intergenic[POU3F2]
Smoking Initiation 6 101153907 rs6922219 G C 0.47 31.2 2.28×10
-8
0.0128 0.00229 383631 183 385831 100953148 101338978 Intron[ASCC3]
Smoking Initiation 6 111644332 rs240963 T C 0.841 72.1 2.03×10
-17
-0.0265 0.00312 383631 37 287818 111578490 111866307 Intron[REV3L]
Smoking Initiation 7 1701592 rs10255004C T 0.432 42.2 8.28×10
-11
-0.015 0.0023 383631 46 45754 1662327 1708080 Intergenic[TFAMP1]
Smoking Initiation 7 3448973 rs2056475 A G 0.746 42.9 5.65×10
-11
-0.0172 0.00262 383631 143 245471 3314356 3559826 Intron[SDK1]
Smoking Initiation 7 96624257 rs2240294 T A 0.444 30 4.25×10
-8
-0.0126 0.0023 383631 8 16261 96622007 96638267 Intron[DLX6-AS1]
Smoking Initiation 7 117523709 rs10233018A G 0.504 43 5.53×10
-11
0.015 0.00228 383631 30 69766 117497811 117567576 Intergenic[CTTNBP2]
Smoking Initiation 8 10153082 rs17151637C T 0.281 35.9 2.12×10
-9
-0.0152 0.00254 383631 48 474267 9803712 10277978 Intron[MSRA]
Smoking Initiation 8 10836472 rs7010246 G A 0.365 30.7 3.04×10
-8
-0.0131 0.00237 383631 182 660014 10519445 11179458 Intron[XKR6]
Smoking Initiation 8 27426077 rs1565735 T A 0.201 67.8 1.77×10
-16
-0.0235 0.00285 383631 2 16051 27426077 27442127 Intergenic[EPHX2]
Smoking Initiation 8 59817068 rs1562612 A G 0.504 37.4 9.73×10
-10
-0.0139 0.00228 384669 30 18107 59799367 59817473 Intron[TOX]
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Smoking Initiation 8 92775372 rs10956808T G 0.422 36.1 1.86×10
-9
-0.0131 0.00218 433216 124 313254 92464180 92777433 Intergenic[RUNX1T1]
Smoking Initiation 8 93201036 rs1899896 C T 0.297 34.9 3.41×10
-9
0.0148 0.0025 383631 37 77665 93184065 93261729 Intergenic[RUNX1T1]
Smoking Initiation 9 16758107 rs10962568G C 0.149 38.7 5.00×10
-10
0.0199 0.00321 383631 4 10708 16749265 16759972 Intron[BNC2]
Smoking Initiation 9 86761781 rs1246264 T C 0.695 38.8 4.82×10
-10
0.0154 0.00248 384669 9 33583 86728457 86762039 Intergenic[SLC28A3]
Smoking Initiation 9 128134034 rs7870475 T C 0.475 44.4 2.73×10
-11
0.0152 0.00229 383631 86 126016 128011403 128137418 Intergenic[GAPVD1]
Smoking Initiation 9 137975748 rs7019640 C T 0.23 32.7 1.10×10
-8
0.0155 0.00271 383631 8 7512 137970849 137978360 Intron[OLFM1]
Smoking Initiation 10 21783634 rs12770228G A 0.315 42.2 8.24×10
-11
0.016 0.00246 383631 60 403745 21746967 22150711 Utr3[C10orf114]
Smoking Initiation 10 27397454 NA C T 0.093 31.1 2.46×10
-8
0.0404 0.00725 112811 3 42396 27397454 27439849 Intergenic[YME1L1]
Smoking Initiation 10 63674885 rs7921378 G C 0.481 42.8 6.06×10
-11
-0.0149 0.00228 383631 16 14732 63666691 63681422 Intron[ARID5B]
Smoking Initiation 10 104045951 NA GT G 0.828 31.7 1.75×10
-8
-0.0314 0.00557 112811 2 83214 104413385 104496598 Deletion[GBF1]
Smoking Initiation 10 104643241 rs12783782G A 0.257 59.9 1.00×10
-14
0.0202 0.00261 383631 55 349356 104611764 104961119 Intron[AS3MT|C10orf32-AS3MT]
Smoking Initiation 10 125680419 rs9423279 C G 0.657 33.3 7.90×10
-9
-0.0139 0.0024 383631 4 20524 125680419 125700942 Intergenic[CPXM2]
Smoking Initiation 11 7950797 rs4523689 A G 0.393 32.4 1.25×10
-8
-0.0133 0.00234 383631 20 314107 7940327 8254433 Intergenic[OR10A6]
Smoking Initiation 11 20129311 rs35891966G A 0.0719 32.4 1.27×10
-8
-0.0237 0.00416 433216 1 1 20129311 20129311 Nonsynonymous[NAV2]
Smoking Initiation 11 27694241 rs2049045 G C 0.187 46.4 9.77×10
-12
-0.0199 0.00293 383631 25 98804 27610041 27708844 Intron[BDNF|BDNF-AS1]
Smoking Initiation 11 85927213 rs1466802 T C 0.775 38.1 6.68×10
-10
0.0169 0.00274 383631 21 398675 85927213 86325887 Intergenic[EED]
Smoking Initiation 11 112839532 rs7948789 A G 0.386 116 6.11×10
-27
0.0252 0.00234 383631 81 77701 112835024 112912724 Intron[NCAM1]
Smoking Initiation 12 56412487 rs1701704 T G 0.341 30.9 2.70×10
-8
-0.0126 0.00227 433216 27 112270 56369911 56482180 Intergenic[IKZF4]
Smoking Initiation 12 57976118 rs11172256A G 0.257 29.8 4.80×10
-8
0.0143 0.00261 383631 14 32524 57975155 58007678 Intron[KIF5A]
Smoking Initiation 12 69686203 rs317660 G A 0.718 35.8 2.23×10
-9
-0.0152 0.00254 383631 25 77611 69637847 69715457 Intergenic[CPSF6]
Smoking Initiation 12 111904371 rs4766578 T A 0.504 30.8 2.83×10
-8
-0.0127 0.00228 384669 14 704633 111495518 112200150 Intron[ATXN2]
Smoking Initiation 12 121111214 rs34067374C T 0.14 30.8 2.80×10
-8
0.0183 0.00329 383631 20 298946 121099149 121398094 Intergenic[CABP1]
Smoking Initiation 12 133451277 rs80032242G A 0.137 30.4 3.54×10
-8
0.0183 0.00332 383631 12 117588 133362170 133479757 Intron[CHFR]
Smoking Initiation 13 38359684 rs4460944 T C 0.527 31.8 1.68×10
-8
0.0129 0.00229 383631 48 11493 38349236 38360728 Intron[TRPC4]
Smoking Initiation 13 100548329 rs7322872 C T 0.791 34 5.55×10
-9
-0.0164 0.00281 383631 6 5127 100545308 100550434 Utr3[CLYBL]
Smoking Initiation 13 101179012 rs837333 T C 0.477 35.7 2.24×10
-9
0.0137 0.00229 383631 56 108502 101150926 101259427 Intron[PCCA]
Smoking Initiation 14 29500106 rs7141236 T C 0.187 34.6 4.01×10
-9
-0.0172 0.00292 384669 72 219248 29316842 29536089 Intergenic[C14orf23]
Smoking Initiation 14 90030280 rs171460 G A 0.26 31 2.52×10
-8
-0.0145 0.0026 383631 13 6221 90027413 90033633 Intron[FOXN3]
Smoking Initiation 15 47616380 rs6493272 T C 0.388 53.4 2.73×10
-13
0.0171 0.00234 383631 86 356232 47615220 47971451 Intron[SEMA6D]
Smoking Initiation 15 47935843 rs1435741 G A 0.43 55 1.18×10
-13
0.0171 0.00231 383631 86 356232 47615220 47971451 Intron[SEMA6D]
Smoking Initiation 15 54119670 rs766614 T G 0.212 31.8 1.75×10
-8
0.0157 0.00279 384669 6 436576 53775670 54212245 Intergenic[WDR72]
Smoking Initiation 16 735921 rs763053 T C 0.225 34.3 4.70×10
-9
-0.016 0.00273 384669 33 54884 694174 749057 Synonymous[WDR24]
Smoking Initiation 16 18058548 rs77878475T A 0.0858 39.5 3.31×10
-10
-0.0256 0.00408 383631 1 1 18058548 18058548 Intergenic[NOMO2]
Smoking Initiation 16 69567781 rs11646575G A 0.439 39.6 3.13×10
-10
0.0145 0.0023 383631 32 196550 69567411 69763960 Intergenic[NFAT5]
Smoking Initiation 18 77458644 rs522180 C T 0.353 45.6 1.47×10
-11
0.0161 0.00239 383631 18 47828 77454237 77502064 Intron[CTDP1]
Smoking Initiation 19 4474725 rs76608582C A 0.0482 32.6 1.15×10
-8
-0.0304 0.00533 383631 1 1 4474725 4474725 Intron[HDGFRP2]
Smoking Initiation 20 29893501 rs6061162 C T 0.912 29.8 4.83×10
-8
0.022 0.00402 383631 27 498697 29471217 29969913 Intron[DEFB116]
Smoking Initiation 20 31140165 rs4911241 C T 0.239 51.9 5.88×10
-13
0.0182 0.00252 433216 13 76764 31093514 31170277 Intergenic[LOC149950]
Drinks per Week 1 4569436 rs780569 T A 0.708 33.2 8.47×10
-9
-0.0161 0.00279 311126 25 171838 4548453 4720290 Intergenic[LOC284661]
Drinks per Week 1 95730588 rs3886141 G C 0.409 31.5 1.96×10
-8
-0.0145 0.00258 311126 25 116820 95622341 95739160 Intergenic[RWDD3]
Drinks per Week 1 165119792 rs10753661G A 0.684 33.2 8.36×10
-9
-0.0157 0.00273 311126 5 5947 165117049 165122995 Intergenic[LMX1A]
Drinks per Week 2 27730940 rs1260326 T C 0.608 176 4.58×10
-40
0.0321 0.00242 357854 1 1 27730940 27730940 Nonsynonymous[GCKR]
Drinks per Week 2 44271496 rs75120545C T 0.0302 33.7 6.29×10
-9
-0.043 0.00741 311126 28 232660 44067220 44299879 Intergenic[LRPPRC]
Drinks per Week 2 45154908 rs528301 G A 0.553 69.6 7.12×10
-17
0.0213 0.00255 311789 5 17874 45141218 45159091 Intergenic[SIX3]
Drinks per Week 2 144272376 rs4233567 C T 0.364 37.5 8.92×10
-10
-0.0161 0.00263 311126 18 109768 144162609 144272376 Intron[ARHGAP15]
Drinks per Week 3 85049088 rs1872552 G A 0.399 44.4 2.73×10
-11
0.0172 0.00259 311789 165 562933 84986088 85549020 Intron[CADM2]
Drinks per Week 3 85593584 rs6780346 C T 0.621 41.1 1.47×10
-10
-0.0168 0.00261 311126 417 247245 85403892 85651136 Intron[CADM2]
Drinks per Week 4 39413780 rs28712821G A 0.608 187 1.67×10
-42
0.0355 0.0026 311126 2 1214 39413780 39414993 Intron[KLB]
Drinks per Week 4 42117559 rs16854020G A 0.13 37.3 1.02×10
-9
0.023 0.00377 311126 6 58502 42117559 42176060 Utr3[BEND4]
Drinks per Week 4 99678179 rs117053285C T 0.00182 0.375 5.40×10
-1
0.0182 0.02972 311126 34 499164 99678179 100177342 Intergenic[TSPAN5]
Drinks per Week 4 100239319 rs1229984 T C 0.98 7882.27×10
-173
0.246 0.00878 334588 1 1 100239319 100239319 Nonsynonymous[ADH1B]
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Drinks per Week 4 100291643 rs6836438 G T 0.134 51.8 6.19×10
-13
-0.0268 0.00372 311126 2 37124 100254520 100291643 Intergenic[ADH1C]
Drinks per Week 4 100291659 rs56022000T C 0.113 4.09 4.30×10
-2
0.00809 0.004 311126 6 76073 100215587 100291659 Intergenic[ADH1C]
Drinks per Week 4 100407531 rs78261064C T 0.00116 10.4 1.28×10
-3
-0.12 0.03722 311126 1 1 100390796 100390796 Intergenic[C4orf17]
Drinks per Week 4 101347141 rs11939510G A 0.0975 7.64 5.71×10
-3
0.0118 0.00427 311126 46 147760 101288442 101436201 Intron[EMCN]
Drinks per Week 4 102702364 rs13105682T G 0.0591 35.4 2.72×10
-9
-0.032 0.00538 311126 3 196434 103001649 103198082 Intergenic[BANK1]
Drinks per Week 4 143617304 rs11943397T C 0.629 32.1 1.43×10
-8
0.0149 0.00262 311126 136 231745 143487451 143719195 Intron[INPP4B]
Drinks per Week 6 12903957 rs9349379 A G 0.406 30.8 2.85×10
-8
0.0134 0.00241 357854 5 108927 12795031 12903957 Intron[PHACTR1]
Drinks per Week 7 69793380 rs6978841 T A 0.184 31.3 2.24×10
-8
-0.0183 0.00327 311126 77 382043 69594503 69976545 Intron[AUTS2]
Drinks per Week 7 153489725 rs6969458 G A 0.466 44.6 2.45×10
-11
0.017 0.00254 311126 31 31145 153463438 153494582 Intergenic[DPP6]
Drinks per Week 9 108755622 rs55932213A G 0.746 32.2 1.41×10
-8
0.0165 0.00291 311126 11 48497 108707126 108755622 Intergenic[TMEM38B]
Drinks per Week 9 109330236 rs4743009 G A 0.201 33.5 6.98×10
-9
-0.0183 0.00317 311126 38 93411 109321180 109414590 Intergenic[ZNF462]
Drinks per Week 10 102626510 rs61873510G T 0.326 33.5 7.14×10
-9
-0.0157 0.0027 311126 3 8966 102626510 102635475 Intergenic[PAX2]
Drinks per Week 11 33204159 rs4756121 G C 0.688 42.8 6.08×10
-11
0.0179 0.00274 311126 83 104350 33113110 33217459 Intron[LOC338739]
Drinks per Week 11 47457539 rs11604680A G 0.32 40.8 1.69×10
-10
-0.0174 0.00272 311126 126 543224 47375193 47918416 Intergenic[RAPSN]
Drinks per Week 11 113412443 rs4309187 A C 0.684 45.9 1.25×10
-11
0.0185 0.00273 311126 21 106298 113317745 113424042 Intergenic[DRD2]
Drinks per Week 11 113660576 rs1713676 A G 0.521 33.7 6.31×10
-9
-0.0147 0.00254 311789 184 305363 113456292 113761654 Intergenic[USP28]
Drinks per Week 11 116073667 rs1894071 A G 0.857 30.2 3.94×10
-8
0.0199 0.00362 311126 8 28722 116073667 116102388 Intergenic[LOC283143]
Drinks per Week 11 121501406 rs10790449T C 0.465 33.6 6.91×10
-9
0.0147 0.00254 311126 28 58174 121495141 121553314 Utr3[SORL1]
Drinks per Week 14 57281154 rs962961 C T 0.326 34.7 3.88×10
-9
-0.0159 0.00271 311126 8 22904 57269825 57292728 Intron[OTX2OS1]
Drinks per Week 14 58833909 rs57044214G A 0.284 35.1 3.17×10
-9
0.0166 0.00281 311126 67 165426 58668484 58833909 Intron[ARID4A]
Drinks per Week 14 94844947 rs28929474C T 0.0198 44.8 2.22×10
-11
-0.0568 0.00849 357854 1 1 94844947 94844947 Nonsynonymous[SERPINA1]
Drinks per Week 16 24810681 rs17177078C T 0.0554 34.9 3.45×10
-9
-0.0327 0.00554 311126 3 117634 24693048 24810681 Intron[TNRC6A]
Drinks per Week 16 28539848 rs4788084 C T 0.418 31.1 2.46×10
-8
-0.0134 0.0024 355949 145 582460 28336882 28919341 Intergenic[NUPR1]
Drinks per Week 16 69745145 rs1800566 G A 0.183 31.5 1.99×10
-8
0.0172 0.00306 357854 103 237972 69549187 69787158 Nonsynonymous[NQO1]
Drinks per Week 16 72356964 rs11648570T C 0.107 31.5 2.04×10
-8
0.023 0.00409 311126 18 626565 72067522 72694086 Intergenic[PMFBP1]
Drinks per Week 16 73912588 rs1104608 G C 0.426 40.6 1.87×10
-10
-0.0163 0.00256 311126 3 17543 73895046 73912588 Intergenic[PSMD7]
Drinks per Week 17 43754850 rs62055691T C 0.225 99.7 1.78×10
-23
-0.0303 0.00303 311126 1459 671979 43572419 44244397 Intron[CRHR1]
Drinks per Week 17 44285531 rs559754274G A 0.225 94.7 2.27×10
-22
-0.0295 0.00303 311789 1300 548426 43785627 44334052 Intron[KIAA1267]
Drinks per Week 17 44843136 rs199528 C T 0.223 88.4 5.27×10
-21
-0.0286 0.00304 311126 47 517285 44345063 44862347 Intron[WNT3]
Drinks per Week 18 40735531 rs62092069G A 0.373 31.9 1.60×10
-8
0.0148 0.00262 311126 80 47623 40702833 40750455 Intergenic[RIT2]
Drinks per Week 19 49248730 rs838145 G A 0.541 46.6 8.86×10
-12
-0.0174 0.00254 311126 16 57061 49206417 49263477 Intron[IZUMO1]
Drinks per Week 20 18693080 rs62217022A G 0.396 32.6 1.10×10
-8
-0.0148 0.00259 311126 102 147966 18569599 18717564 Intron[DTD1]
Drinks per Week 20 31607551 rs61734341G C 0.0598 32.7 1.09×10
-8
-0.0285 0.00499 357854 6 373090 31248265 31621354 Nonsynonymous[BPIL1]
Drinks per Week 22 41941243 rs9607812 G A 0.187 38 7.21×10
-10
-0.02 0.00325 311126 147 222403 41749630 41972032 Intergenic[POLR3H]
Drinks per Week 22 46481623 rs17884691G A 0.248 32.7 1.08×10
-8
-0.0168 0.00294 311126 2 1022 46480602 46481623 Intergenic[LOC400931]
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Supplemental Table 7. Bayesian Fine Mapping with Prior Informed by Functional Annotations, all Variants with Posterior Probability of Association Greater than .80 are shown
PHENOTYPE POSITION RS Number REF/ALT AF P-VALUE BETA SE Posterior Probablity of Association Annotation
Cigarettes per Day 8:42550498 rs6474412 C/T 0.775 3.40×10
-16
0.035 0.0043 0.95 Intergenic[Intergenic]
Cigarettes per Day 9:136478355 rs3025343 G/A 0.117 5.50×10
-11
0.037 0.0056 0.92 Intergenic[Intergenic]
Cigarettes per Day 15:78882925 rs16969968 G/A 0.337 2.50×10
-139
0.096 0.0038 0.92 Asp398Asn[CHRNA5]
Cigarettes per Day 15:79211424 rs147125452 T/C 0.026 8.50×10
-10
-0.078 0.0127 0.86 Intergenic[Intergenic]
Cigarettes per Day 19:41353107 rs56113850 T/C 0.575 3.00×10
-68
0.072 0.0041 1 Intron[CYP2A6]
Cigarettes per Day 20:61984317 rs6011779 C/T 0.806 7.40×10
-10
-0.032 0.0051 0.83 Intron[CHRNA4]
Pack Years 9:136478355 rs3025343 G/A 0.114 2.30×10
-21
0.05 0.0053 0.98 Intergenic[Intergenic]
Pack Years 15:78806023 rs8034191 T/C 0.338 5.80×10
-118
0.082 0.0036 0.99 Intron[AGPHD1]
Pack Years 19:41353107 rs56113850 T/C 0.572 5.60×10
-25
0.038 0.0037 0.8 Intron[CYP2A6]
Pack Years 20:61991833 rs45497800 C/T 0.087 1.50×10
-16
0.054 0.0066 1 Intron[CHRNA4]
Smoking Initiation 1:94078440 rs236345 A/G 0.221 9.10×10
-8
-0.015 0.0027 0.84 Intron[BCAR3]
Smoking Initiation 1:108507209 rs56193625 G/A 0.0556 3.80×10
-7
-0.025 0.005 0.85 Intron[VAV3]
Smoking Initiation 1:179783167 rs147052174 G/T 0.0181 1.20×10
-7
0.043 0.008 1 Gly116Val[FAM163A]
Smoking Initiation 1:237841390 rs34967813 A/G 0.312 8.10×10
-7
-0.011 0.0023 0.98 Gln2958Arg[RYR2]
Smoking Initiation 2:64092819 rs140144265 C/T 0.00232 4.90×10
-8
-0.129 0.0237 0.91 Intron[UGP2]
Smoking Initiation 5:106834363 rs72789632 C/T 0.13 2.40×10
-9
-0.02 0.0034 0.93 Intron[EFNA5]
Smoking Initiation 5:118691561 rs139564712 C/T 0.00055 2.40×10
-7
0.464 0.0897 0.93 Intron[TNFAIP8]
Smoking Initiation 7:121983843 rs2289705 A/G 0.214 5.50×10
-8
0.015 0.0028 0.86 Intron[CADPS2]
Smoking Initiation 8:27442127 rs73229090 C/A 0.118 3.40×10
-15
-0.028 0.0035 0.85 Intergenic[Intergenic]
Smoking Initiation 9:16749265 rs56348592 A/G 0.145 5.80×10
-10
0.02 0.0032 0.8 Intron[BNC2]
Smoking Initiation 9:86755967 rs1030856 A/G 0.68 2.40×10
-9
0.015 0.0024 0.85 Intergenic[Intergenic]
Smoking Initiation 11:20129311 rs35891966 G/A 0.0719 1.30×10
-8
-0.024 0.0042 1 Val2251Ile[NAV2]
Smoking Initiation 11:27679916 rs6265 C/T 0.19 1.90×10
-10
-0.017 0.0027 0.83 Val66Met[BDNF]
Smoking Initiation 14:31774324 rs61754158 C/T 0.009 1.40×10
-6
-0.055 0.0114 0.87 Gly1676Arg[HEATR5A]
Smoking Initiation 19:4474725 rs76608582 C/A 0.0482 1.20×10
-8
-0.03 0.0053 0.95 Intron[HDGFRP2]
Smoking Initiation 19:41084693 rs814518 G/A 0.304 5.50×10
-8
-0.013 0.0025 0.84 Intron[SHKBP1]
Drinks per Week 2:27730940 rs1260326 T/C 0.61 4.60×10
-40
0.032 0.0024 1 Leu446Pro[GCKR]
Drinks per Week 4:39413780 rs28712821 G/A 0.608 1.70×10
-42
0.035 0.0026 0.94 Intron[KLB]
Drinks per Week 4:42117559 rs16854020 G/A 0.13 1.00×10
-9
0.023 0.0038 0.98 Utr3[BEND4]
Drinks per Week 4:100239319 rs1229984 T/C 0.98 2.30×10
-173
0.246 0.0088 1 His48Arg[ADH1B]
Drinks per Week 4:103198082 rs13135092 A/G 0.082 3.70×10
-16
-0.038 0.0046 0.91 Intron[SLC39A8]
Drinks per Week 7:20824614 rs34908430 C/T 0.299 5.60×10
-8
-0.015 0.0027 0.99 Synonymous[SP8]
Drinks per Week 7:99229435 rs3735453 T/C 0.077 4.30×10
-6
-0.022 0.0048 0.84 Utr3[ZNF498]
Drinks per Week 12:50263148 rs7132908 G/A 0.375 1.90×10
-7
-0.013 0.0025 0.89 Utr3[FAIM2]
Drinks per Week 14:94844947 rs28929474 C/T 0.02 2.20×10
-11
-0.057 0.0085 1 Glu366Lys[SERPINA1]
Drinks per Week 16:69745145 rs1800566 G/A 0.183 2.00×10
-8
0.017 0.0031 0.97 Pro153Ser[NQO1]
Drinks per Week 19:49248730 rs838145 G/A 0.541 8.90×10
-12
-0.017 0.0025 0.95 Intron[IZUMO1]
Drinks per Week 20:25096789 rs1884265 A/C 0.79 9.50×10
-8
0.017 0.0031 0.87 Intergenic[Intergenic]
